Inhibition of polyoma virus replication
Antisense oligonucleotides targeting polyomavirus T antigen pre-mRNA splice sites inhibit viral replication and protein expression, addressing the inadequacies of current treatments for polyomavirus infections in immunocompromised individuals.
Patent Information
- Application Number
- JP2024123185
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-03-02
- Filing Date
- 2024-07-30
- Publication Date
- 2024-11-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for polyomavirus infections, particularly in immunocompromised individuals, are inadequate in preventing reactivation and replication, leading to pathological conditions.
Development of antisense oligonucleotides that specifically target the splice donor and acceptor sites of polyomavirus T antigen pre-mRNA, modulating splicing and reducing viral protein expression and replication.
The antisense oligonucleotides effectively inhibit polyomavirus replication and protein expression, reducing the severity and frequency of infections in immunocompromised hosts, particularly in transplant recipients.
Smart Images

Figure 2024156786000008 
Figure 2024156786000009 
Figure 2024156786000010
Abstract
Description
[Technical field]
[0001] The present invention relates to a molecule that specifically binds to polyomavirus RNA.In some embodiments, the molecule comprises an antisense oligonucleotide that recognizes the pre-mRNA that comprises the coding region of the T antigen of polyomavirus.Examples of polyomaviruses are human polyomaviruses, such as JC virus (JCV), BK virus (BKV) or Merkel cell virus (MCV). [Background technology]
[0002] Polyomaviruses are small, non-enveloped, double-stranded DNA viruses whose natural hosts are usually mammals and birds. Infections in adults are mostly asymptomatic, but can become pathological if the immune system is compromised. Non-limiting examples of human polyomaviruses are BK virus, JC virus, and Merkel cell virus.
[0003] Both JCV and BKV are opportunistic pathogens that infect human populations during early childhood (Leploeg, MD et. al., Clinical Infectious Diseases, 2001). Seroprevalence in adults is high. Both viruses are thought to remain latent in the host's kidney cells (Wunderink, HF et. al., American Journal of Transplantation, 2017). Reactivation can occur, for example, in immunosuppressed individuals (Wunderink, HF et. al., American Journal of Transplantation, 2017; Parajuli, S. et. al., Clinical Transplantation, 2018; Gard, L. et. al., PLoS One, 2017).
[0004] Polyomaviruses share a common genome structure. Polyomaviruses have genes that are expressed both early and late in the infection cycle. Both early and late genes generate RNAs that can be translated into various proteins by differential splicing. As shown in Figure 1, late RNAs usually code for three capsid proteins, whereas early genes often code for small and large T antigens and one or more other alternatively spliced coding regions (Helle, F. et. al., Viruses, 2017).
[0005] WO2015 / 042466 describes an antisense oligonucleotide-based approach to inhibit the replication and proliferation of JC virus. The antisense oligonucleotides disclosed therein can be oligodeoxyribonucleotides (ODNs) or chimeric oligonucleotides with ODNs flanked internally by one or more nucleotides with a nuclease-resistant backbone. The latter render the RNA:oligonucleotide hybrid sensitive to the action of RNase H. The deoxyribonucleotides have at least four deoxyribonucleotides internally and are flanked by nuclease-resistant regions with 2'-sugar modified nucleotides. The antisense oligonucleotides are directed to specific sequences present in the mRNA of JC virus.
[0006] In some embodiments, the present invention provides antisense oligonucleotides capable of modulating splicing of polyomavirus T antigen pre-mRNA. The antisense oligonucleotides may have sequences complementary to splice donor and / or splice acceptor sites in the pre-mRNA. The antisense oligonucleotides may have sequences complementary to one or more intronic nucleobases flanking an exon (see FIG. 2). In some embodiments, the antisense oligonucleotides render the duplex between the antisense oligonucleotide and its polyomavirus T antigen pre-mRNA target resistant to the action of RNase H. Summary of the Invention
[0007] The present invention provides antisense oligonucleotides 12-30, preferably 17, 18, 19 or 20-30 nucleobases in length comprising a sequence which is the reverse complement of a contiguous stretch of at least 12 nucleobases of polyomavirus large T antigen pre-mRNA, which antisense oligonucleotides are capable of modulating splicing of said large T antigen pre-mRNA in a cell (see FIG. 1).
[0008] Splice regulator antisense oligonucleotides of the invention typically require a contiguous stretch of at least 17, preferably at least 18, more preferably at least 19, more preferably at least 20 nucleobases complementary to the polyomavirus large T antigen pre-mRNA.
[0009] The present invention also provides antisense oligonucleotides 12-30, preferably 17, 18, 19 or 20-30 nucleobases in length comprising a sequence which is the reverse complement of a contiguous stretch of at least 12 nucleobases of a Polyomavirus large T antigen pre-mRNA, which stretch includes a splice donor, splice acceptor sequence or a combination thereof in said pre-mRNA, wherein the splice donor sequence or splice acceptor sequence is preferably a Polyomavirus large T antigen splice acceptor or a Polyomavirus large T antigen splice donor sequence.
[0010] Further provided is an antisense oligonucleotide of 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases in length that is at least 80% complementary to nucleotides 4537-4596 or 4881-4940 taken from NC_001538 and includes at least complementarity to a splice donor or splice acceptor sequence in the respective region.
[0011] Also provided are antisense oligonucleotides 12-30, preferably 17, 18, 19 or 20-30 nucleobases in length, preferably at least 80% complementary to nucleotides in the region 4397-4456 or the region 4741-4800 taken from NC_001699 and including at least complementarity to a splice donor or splice acceptor sequence in the respective region.
[0012] Also provided are antisense oligonucleotides of 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases in length, preferably at least 80% complementary to nucleotides in the region 4299-4358 or the region 4686-4745 taken from NC_009238 and including at least complementarity to a splice donor or splice acceptor sequence in the respective region.
[0013] Also provided are antisense oligonucleotides 12-30, preferably 17, 18, 19 or 20-30 nucleobases in length that are preferably at least 80% complementary to nucleotides in the region 4477-4536 or the region 4876-4935 taken from NC_009539 and that include at least complementarity to a splice donor or splice acceptor sequence in the respective region.
[0014] Also provided are antisense oligonucleotides 12-30, preferably 17, 18, 19 or 20-30 nucleobases in length, preferably at least 80% complementary to nucleotides in the region 4693-4752 or region 5124-5183 taken from NC_010277 and including at least complementarity to a splice donor or splice acceptor sequence in the respective region.
[0015] Also provided are antisense oligonucleotides 12-30, preferably 17, 18, 19 or 20-30 nucleobases in length, preferably at least 80% complementary to nucleotides in the region 4264-4323 or the region 4654-4713 obtained from NC_014406 and including at least complementarity to a splice donor or splice acceptor sequence in the respective region.
[0016] Also provided are antisense oligonucleotides 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases in length, preferably at least 80% complementary to nucleotides in the region 4272-4331 or region 4677-4736 taken from NC_014407 and including at least complementarity to a splice donor or splice acceptor sequence in the respective region.
[0017] Also provided are antisense oligonucleotides 12-30, preferably 17, 18, 19 or 20-30 nucleobases in length, preferably at least 80% complementary to nucleotides in the region 4352-4411 or region 4765-4824 taken from NC_014361 and including at least complementarity to a splice donor or splice acceptor sequence in the respective region.
[0018] Also provided are antisense oligonucleotides 12-30, preferably 17, 18, 19 or 20-30 nucleobases in length, preferably at least 80% complementary to nucleotides in the region 4408-4467 or the region 4760-4819 taken from NC_015150 and including at least complementarity to a splice donor or splice acceptor sequence in the respective region.
[0019] Also provided are antisense oligonucleotides 12-30, preferably 17, 18, 19 or 20-30 nucleobases in length, preferably at least 80% complementary to nucleotides in the region 4303-4362 or the region 4658-4717 obtained from NC_018102 and including at least complementarity to a splice donor or splice acceptor sequence in the respective region.
[0020] Also provided are antisense oligonucleotides 12-30, preferably 17, 18, 19 or 20-30 nucleobases in length, preferably at least 80% complementary to nucleotides in the region 4159-4218 or the region 4504-4563 taken from NC_020106 and including at least complementarity to a splice donor or splice acceptor sequence in the respective region.
[0021] Also provided are antisense oligonucleotides 12-30, preferably 17, 18, 19 or 20-30 nucleobases in length, preferably at least 80% complementary to nucleotides in the region 4392-4451 or region 4791-4850 taken from NC_020890 and including at least complementarity to a splice donor or splice acceptor sequence in the respective region.
[0022] Also provided are antisense oligonucleotides 12-30, preferably 17, 18, 19 or 20-30 nucleobases in length, preferably at least 80% complementary to nucleotides in the region 4471-4530 or the region 4859-4918 taken from NC_024118 and including at least complementarity to a splice donor or splice acceptor sequence in the respective region.
[0023] The antisense oligonucleotides described herein preferably comprise at least 12 contiguous nucleic acid bases of SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; SEQ ID NO:6; SEQ ID NO:7; SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10; SEQ ID NO:11; SEQ ID NO:12; SEQ ID NO:13; SEQ ID NO:14; SEQ ID NO:15; SEQ ID NO:16; SEQ ID NO:17; SEQ ID NO:18; SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:22; SEQ ID NO:23; SEQ ID NO:24; SEQ ID NO:25; SEQ ID NO:26 or SEQ ID NO:27, wherein the at least 12 nucleotides preferably comprise the reverse complement of the splice donor site, splice acceptor site or a combination thereof of the target pre-mRNA, i.e., the reverse complement of the splice donor / acceptor site of the respective polyomavirus large T antigen pre-mRNA. In a preferred embodiment, the antisense oligonucleotides described herein are selected from the group consisting of SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; SEQ ID NO:6; SEQ ID NO:7; SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10; SEQ ID NO:11; SEQ ID NO:12; SEQ ID NO:13; SEQ ID NO:14; SEQ ID NO:15; SEQ ID NO:16; SEQ ID NO:17; SEQ ID NO:18; SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:22; SEQ ID NO:23; SEQ ID NO:24; SEQ ID NO:25; SEQ ID NO:26 or SEQ ID NO:27; preferably SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:6; SEQ ID NO:7; SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10; SEQ ID NO:20; SEQ ID NO:21; and preferably at least 17, preferably at least 18, preferably at least 19, more preferably at least 20 contiguous nucleic acid bases of sequence number 22; sequence number 23; sequence number 24 or sequence number 25; sequence number 1; sequence number 2; sequence number 3; sequence number 4; sequence number 20; sequence number 21; sequence number 22; sequence number 23; sequence number 24 or sequence number 25, which nucleotides preferably comprise the reverse complement of the splice donor site, splice acceptor site or a combination thereof of the target pre-mRNA, i.e., the reverse complement of the splice donor / acceptor site of the respective polyomavirus large T antigen pre-mRNA.Antisense oligonucleotides may have one mismatch with the described sequence, but the mismatch is not at the beginning or end of the continuous stretch.For example, an AON having a continuous stretch of 17 nucleotides with a mismatch at position 1 or 17 will actually have a continuous stretch of 16 nucleotides.
[0024] Also provided is a method of inhibiting polyomavirus replication in a cell, comprising providing to a cell infected with said polyomavirus an antisense oligonucleotide of the invention specific for the polyomavirus.
[0025] The present invention further provides a method of preparing a graft for transplantation, which method comprises providing donor cells, preferably donor kidney cells, with an antisense oligonucleotide of the invention specific for polyomavirus.
[0026] Also provided is a method of treating a polyomavirus infection in a subject, comprising administering to an individual in need thereof an antisense oligonucleotide of the invention specific for a polyomavirus.
[0027] Further provided is a method of administering an antisense oligonucleotide to an individual for hybridization to a complementary RNA sequence in cells of the individual, characterized in that the antisense oligonucleotide is a chimeric antisense oligonucleotide comprising a first and a second region, wherein the first region comprises one or more deoxyribonucleotides and the second region comprises at least one 2'-O-(2-methoxy-ethyl) nucleotide (see FIG. 7).
[0028] Further provided is a method of inhibiting polyomavirus replication in a cell, the method comprising providing to said cell an antisense oligonucleotide of 12-30 nucleotides in length comprising a sequence which is the reverse complement of a contiguous stretch of at least 12 nucleobases of polyomavirus large T antigen pre-mRNA, the antisense oligonucleotide being capable of modulating splicing of said large T antigen pre-mRNA. The antisense oligonucleotide is preferably an antisense oligonucleotide as described herein, preferably an antisense oligonucleotide of SEQ ID NO: 1-25, as described herein or modified herein. [Brief description of the drawings]
[0029] [Figure 1](Figure 1-1) Schematic of the BK virus genome and sequence similarities of various BK virus genome subtypes. Left: The BK virus genome encodes five major proteins, namely small t antigen and large T antigen (early genes), as well as agnoprotein and the major capsid proteins VP1, VP2 and VP3 (late genes). The viral genome also contains a non-coding region (NCCR), which contains both origins of replication and promoter regions for transcription factors that drive expression of early and late genes along with replication of the viral genome. Of note, alternative splicing of early and late pre-mRNAs, along with alternative splicing that determines the ratio of VP1, VP2 or VP3 generated, results in numerous protein isoforms, including small t antigen, truncated T antigen (two introns) and large T antigen (one intron). However, it is important to note that the major splice variant generated for the late region is the mature mRNA that mainly encodes VP1. Continued (Figure 1-2): The genomic sequence of the early region encodes the T antigen proteins, namely, small t (tAg), truncated T (truncTAg) and large T antigen (TAg). tAg plays a crucial role in driving the infected cells into the S phase, allowing TAg-mediated viral genome replication. Furthermore, TAg binds to the NCCR to drive the expression of pre-mRNAs of the late region. This results in the production of VP1, VP2 and VP3, which are essential for viral DNA encapsulation.
[0030] [Diagram 2]The entire gene sequence of TAg (including intron sequences) was aligned against 245 unique BK polyomavirus isolates (downloaded from the publicly available NCBI database) using clustalW (package "msa" in R). From these records, only isolates with reported whole genomes were used for splice site conservation in TAg. The Dunlop strain was used as the reference genome. Phylogenetic trees were constructed using the UPGMA method (packages "phangorn" and "ggtree" in R). Sequence logos were constructed for acceptor and donor splice sites to show nucleotide-specific conservation between subtypes (package "msa" in R).
[0031] [Diagram 3] Composition of antisense oligonucleotides regulating splicing of BKPyV TAg. Sequences of antisense oligonucleotides (AONs) targeting the exon 1-intron junction (AONs #1, #2, and #3) and the intron-exon 2 junction (AONs #4 and #5) of BKPyV TAg.
[0032] [Figure 4] TAg splicing-modulating AONs reduce the expression levels of TAg and VP1 mRNA in human epithelial cells infected with BKPyV. Left: Reduction in TAg RNA levels in HK2 cells treated with scrambled AONs vs. splicing-modulating AONs #1, #2, #3, #4, and #5 7 days after infection with BKPyV virus at a multiplicity of infection of about 100 (n=5; p<0.05). Right: Reduction in VP1 RNA levels in HK2 cells treated with scrambled AONs vs. splicing-modulating AONs #1, #2, #3, #4, and #5 7 days after infection with BKPyV virus at a multiplicity of infection of about 100 (n=5; p<0.05).
[0033] [Diagram 5] TAg splicing-modulating AONs reduce the expression level of VP1 protein in human epithelial cells infected with BKPyV. Western blot analysis of HK2 cell lysates harvested 7 days after infection with BK polyomavirus at a multiplicity of infection of about 100. Compared to HK2 cells treated with scrambled AONs, AONs #2, #3 and #4 obviously suppress the expression level of VP1 protein (n=4).
[0034] [Figure 6] TAg splicing-modulating AONs reduce BK virus replication. Viral DNA concentrations in culture supernatants were measured by PCR analysis for VP1 in the BKPyV genome. HK2 cells treated with AONs #2, #3, and #4 consistently showed lower levels of BKPyV genome in culture supernatants compared to HK2 cells treated with scrambled AONs.
[0035] [Figure 7] Chemical modifications to AONs. Several chemical modifications that have been applied to the present TAg splicing-regulating AONs are depicted (phosphorothioate backbone and 2'-OMe at the ribose moiety). Other embodiments of these AONs may use 2'-MOE or 2'-cEt modifications at this position. These modifications primarily serve to improve the stability of the AONs.
[0036] [Figure 8] Sequence similarity to 13 polyomaviruses known to have human hosts. Notably, these strains encompass the genera Alpha, Beta, and Delta, most of which have been identified recently. As shown in the phylogenetic tree information on the left side of this figure, BKPyV and JCPyV share significant sequence similarity, suggesting that their co-localization in renal proximal tubule epithelial cells lends itself to targeting using the splicing-modulating AONs described herein.
[0037] [Figure 9] Design of AONs that can be used to target other polyomaviruses. In parallel with the TAg splicing-modulating AONs of BK and JC viruses described above, AONs were designed based on the possibility that AONs could also target human polyomavirus 3 (Karolinska Institute or KI), human polyomavirus 4 (Washington University or WU) and human polyomavirus 5 (Merkel cell virus or MCV). For human polyomaviruses 3-5, two AONs targeting the exon 1-intron junction and two targeting the intron-exon 2 junction were designed, in contrast to the three AONs at the exon 1-intron site.
[0038] [Figure 10] Schematic diagram of the BK virus genome and BKV-targeted AON. Part 1 (Figure 10-1): The BK virus genome encodes six major proteins, namely small t antigen and large T antigen (early genes), as well as agnoprotein and the major capsid proteins VP1, VP2 and VP3 (late genes). The viral genome also contains a non-coding region (NCCR), the sequence of which includes both origins of replication and promoter regions involved in the recruitment of transcription factors that drive the expression of early and late genes in coordination with viral genome replication. As shown in Figure 1, alternative splicing of early and late pre-mRNAs, with alternative splicing determining the ratio of VP1, VP2 or VP3 generated, results in numerous protein isoforms, including small t antigen, truncated T antigen (two introns) and large T antigen (one intron). The major splice variant generated for the late region results mainly in the expression of VP1. Part 2 (Figure 10-2): AON sequences used to target the exon-intron junction of BKV large T antigen (TAg) shown in the top panel. Part 3 (Figure 10-3): Schematic showing the binding sites for AONs at the exon-intron junction of BKV TAg.
[0039] [Figure 11] Bioinformatics analysis of TAg splice site conservation towards the design of universal BKV-targeting AONs. Part 1 (Figure 11-1): Phylogenetic tree with whole gene TAg sequences for unique BKV isolates / strains showing clear differences among BKV subgroups. Part 2 (Figure 11-2): Sequence logos for TAg splice sites (20 nucleotides) with flanking regions showing high sequence conservation among subgroups. Sequences of antisense oligonucleotides (AONs) targeting exon 1-intron junctions (HYB_01, HYB_02, HYB_03, HYB_06, HYB_07, HYB_08, HYB_09, HYB_10 and HYB_11) and intron-exon 2 junctions (HYB_04, HYB_05, HYB_12 and HYB_13) of BKV TAg are provided.
[0040] [Figure 12] TAg splicing-modulating AONs reduce the expression levels of TAg mRNA in human kidney epithelial cells infected with BKV. Reduction of TAg RNA levels in HK2 cells treated with scrambled AONs versus BKV-targeted AONs (after treatment, cells were infected with BKV at a multiplicity of infection of approximately 100) (n=3 biological replicates). Note: HYB_14 binds exclusively to the exonic region of TAg exon 1 and does not target exon-intron boundaries.
[0041] [Figure 13] TAg splicing-modulating AONs reduce VP1 mRNA expression levels in human kidney epithelial cells infected with BKV. Reduction of VP1 RNA levels in HK2 cells treated with scrambled AONs versus BKV-targeted AONs (after treatment, cells were infected with BKV at a multiplicity of infection of approximately 100) (n=3 biological replicates). Note: HYB_14 binds exclusively to the exonic region of TAg exon 1 and does not target exon-intron boundaries.
[0042] [Figure 14] TAg splicing-modulating AONs reduce VP1 protein expression levels in human kidney epithelial cells infected with BKV. Representative Western blot analysis of cell lysates harvested from HK2 cells treated with BKV-targeted AONs. The blot shows VP1 protein levels in lysates harvested 7 days after infection with BK polyomavirus at a multiplicity of infection of approximately 100 (n=3 biological replicates).
[0043] [Figure 15] Quantification of VP1 protein expression levels in human kidney epithelial cells infected with BKV after treatment with BKV-targeting AONs. Quantification of Western blot analysis of HK2 cell lysates harvested 7 days after infection with BK polyomavirus at a multiplicity of infection of approximately 100. HK2 cells treated with scrambled AONs were used as a control. All values are in log2 scale (n=3 biological replicates). Note: HYB_14 binds exclusively to the exonic region of TAg exon 1 and does not target exon-intron boundaries.
[0044] [Figure 16] TAg splicing-modulating AONs reduce BKV DNA replication. Viral particle concentrations in culture supernatants 7 days after infection were measured by PCR analysis against VP1 in the BKV genome. HK2 cells treated with BKV-targeting AONs consistently show lower levels of BKV particles in culture supernatants compared to HK2 cells treated with scrambled AONs. Data represent biological n=3.
[0045] [Figure 17]TAg splicing-modulating AONs reduce the level of HK2 reinfection. Culture supernatants were removed from HK2 cells pretreated with BKV-targeting AONs and infected with BKV after 7 days. The supernatants were used to infect untreated HK2 cells (2 h), which were then cultured for 7 days and immunohistochemically stained for TAg and hoechst (for nuclei). The percentage positive cells were then measured and shown relative to cells treated with scrambled AONs. Data are representative of biological n=3.
[0046] [Figure 18] Heatmap depicting the cumulative effect of treatment with BKV-targeted AONs on various aspects of BKV infection of HK2 cells. Summary of observed effects on TAg and VP1 mRNA, VP1 protein, viral particle production and reinfection. Scale indicates black represents little to no effect and white represents large effect (2 log fold change compared to Scrambled, n=3).
[0047] [Figure 19] TAg splicing-modulating lead AONs reduce expression levels of TAg mRNA in human kidney epithelial cells infected with BKV. Reduction of TAg RNA levels in HK2 cells treated with scrambled AONs versus BKV-targeting lead AONs (HYB_01, HYB_03 or HYB_11) (after treatment, cells were infected with BKV at a multiplicity of infection of approximately 100) (n=3 biological replicates). Note: SAN_73 and SAN_74 are previously reported AONs (16 nucleotides long). These data are representative of a biological n=3.
[0048] [Figure 20]TAg splicing-modulating lead AONs reduce the expression level of VP1 mRNA in human kidney epithelial cells infected with BKV. Reduction of VP1 mRNA levels in HK2 cells treated with scrambled AONs versus BKV-targeted lead AONs (HYB_01, HYB_03 or HYB_11) (after treatment, cells were infected with BKV at a multiplicity of infection of approximately 100). Note: SAN_73 and SAN_74 are previously reported AONs (16 nucleotides long). These data are representative of biological n=3.
[0049] [Figure 21] TAg splicing modulating lead AONs reduce VP1 protein expression levels in BKV-infected human kidney epithelial cells. Representative Western blot visualization of VP1 protein levels in cell lysates harvested from HK2 cells treated with BKV-targeting lead compound AONs and 7 days after infection with BK polyomavirus at a multiplicity of infection of approximately 100 (n=3 biological replicates).
[0050] [Figure 22] TAg splicing-modulating lead AONs reduce VP1 protein expression levels in human kidney epithelial cells infected with BKV. Reduction in VP1 protein levels in HK2 cells treated with scrambled AONs versus HK2 cells treated with BKV-targeted lead AONs (HYB_01, HYB_03 or HYB_11) (after treatment, cells were infected with BKV at a multiplicity of infection of approximately 100). Note: SAN_73 and SAN_74 are previously reported AONs (16 nucleotides long). These data are representative of biological n=3.
[0051] [Diagram 23]TAg splicing-modulating lead AONs reduce viral particle production in human kidney epithelial cells infected with BKV. Reduced viral particle levels in HK2 cells treated with scrambled AONs versus BKV-targeted lead AONs (HYB_01, HYB_03 or HYB_11) (after treatment, cells were infected with BKV at a multiplicity of infection of approximately 100). Note: SAN_73 and SAN_74 are previously reported AONs (16 nucleotides long). These data are representative of biological n=3.
[0052] [Figure 24] TAg splicing-modulating lead AONs reduce the level of HK2 reinfection. Culture supernatants were removed from HK2 cells pretreated with BKV-targeting lead AONs (HYB_01, HYB_03 or HYB_11) and infected with BKV after 7 days. The supernatants were used to infect untreated HK2 cells (2h), which were then cultured for 7 days and immunohistochemically stained for TAg and Hoechst (for nuclei). The percentage positive cells were then measured and shown relative to cells treated with scrambled AONs. Data are representative of biological n=3.
[0053] [Diagram 25] Heatmap depicting the cumulative effect of treatment with BKV-targeting lead compound AONs on various aspects of BKV infection of HK2 cells. Summary of observed effects on TAg and VP1 mRNA, VP1 protein, viral particle production and reinfection for HK2 cells pretreated with lead compound AONs (HYB_01, HYB_03 or HYB_11). Scale indicates black represents little to no effect and white represents large effect (2 log fold change compared to scramble, n=3).
[0054] [Figure 26]Efficacy of TAg splicing-modulating AONs to reduce TAg mRNA expression in HK2 pre-infected with BKV. In contrast to pretreatment with AONs, we first infected HK2 cells with BKV and then used them to evaluate the efficacy of AONs to reduce TAg mRNA expression levels. Left panel: A single dose of AONs after infection significantly reduced TAg mRNA expression levels, although the addition of AONs at later time points did not appear to be effective. Right panel: Multiple doses of BKV-targeted AONs more strongly reduced TAg mRNA expression levels. Note that RNA expression levels were measured at t=7 post-infection for all treatment time points, resulting in shorter exposures for later treatments compared to earlier treatments. Data are representative of a biological n=1.
[0055] [Figure 27] Efficacy of TAg splicing-modulating AONs to reduce VP1 mRNA expression in HK2 pre-infected with BKV. In contrast to pretreatment with AONs, we first infected HK2 cells with BKV and then used them to evaluate the efficacy with which AONs could reduce VP1 mRNA expression levels. Left panel: A single dose of AONs after infection significantly reduced VP1 mRNA expression levels, although the addition of AONs at later time points did not appear to be effective. Right panel: Multiple doses of BKV-targeted AONs more strongly reduced VP1 mRNA expression levels. Note that RNA expression levels were measured at t=7 post-infection for all treatment time points, resulting in shorter exposures for later treatments compared to earlier treatments. Data are representative of a biological n=1.
[0056] [Figure 28]TAg splicing-modulating lead AONs reduce expression levels of TAg mRNA in human primary proximal tubule epithelial cells (hPTECs) infected with BKV. Reduction in TAg RNA levels in hPTECs treated with scrambled AONs versus hPTECs treated with BKV-targeted lead AONs (HYB_01, HYB_03, or HYB_11) or HYB_14 (after treatment, cells were infected with BKV at a multiplicity of infection of approximately 100) (n=3 biological replicates). These data are representative of a biological n=3.
[0057] [Figure 29] TAg splicing-modulating lead AONs reduce VP1 mRNA expression levels in BKV-infected hPTECs. Reduction in VP1 RNA levels in hPTECs treated with scrambled AONs versus BKV-targeted lead AONs (HYB_01, HYB_03, or HYB_11) or HYB_14 (after treatment, cells were infected with BKV at a multiplicity of infection of approximately 100) (n=3 biological replicates). These data are representative of a biological n=3.
[0058] [Diagram 30] TAg splicing-modulating lead AONs reduce VP1 and VP3 protein expression levels in BKV-infected hPTECs. Representative Western blot visualization of VP1 and VP3 protein levels in cell lysates harvested from hPTECs 7 days after treatment with BKV-targeting lead compound AONs and infection with BK polyomavirus at a multiplicity of infection of approximately 100 (VP1 and GAPDH: n=3 biological replicates, VP3: n=1).
[0059] [Diagram 31]TAg splicing-modulating lead AONs reduce VP1 protein expression levels in hPTECs infected with BKV. Reduced VP1 protein levels in hPTECs treated with scrambled AONs versus hPTECs treated with BKV-targeted lead AONs (HYB_01, HYB_03, or HYB_11) or HYB_14 (after treatment, cells were infected with BKV at a multiplicity of infection of approximately 100) (n=3 biological replicates). These data are representative of a biological n=3.
[0060] [Diagram 32] TAg splicing-modulating lead AONs reduce VP3 protein expression levels in hPTECs infected with BKV. Reduced VP3 protein levels in hPTECs treated with scrambled AONs versus BKV-targeted lead AONs (HYB_01, HYB_03, or HYB_11) or HYB_14 (after treatment, cells were infected with BKV at a multiplicity of infection of approximately 100) (n=3 biological replicates). These data are representative of a biological n=1.
[0061] [Diagram 33] TAg splicing-modulating lead AONs reduce viral particle production in hPTECs infected with BKV. Reduced viral particle levels in hPTECs treated with scrambled AONs versus BKV-targeted lead AONs (HYB_01, HYB_03, or HYB_11) or HYB_14 (after treatment, cells were infected with BKV at a multiplicity of infection of approximately 100). These data are representative of biological n=3.
[0062] [Diagram 34]Heatmap depicting the cumulative effect of treatment with BKV-targeting lead compound AONs on various aspects of BKV infection of hPTEC. Summary of observed effects on TAg and VP1 mRNA, VP1 protein and viral particle production on hPTECs pretreated with lead compound AONs (HYB_01, HYB_03 or HYB_11) or HYB_14. Scale indicates that black represents little to no effect and white represents a large effect (2 log fold change compared to Scrambled, n=3).
[0063] [Diagram 35] RNA-seq analysis of splicing modulation induced by BKV-targeted lead AON. The upper part of the panel shows the primary transcript and splicing events, and the lower part of the panel shows the observed splicing patterns and z-scores, indicating that our BKV-targeted AON indeed modulates splicing. Events are observed at the exon 1-intron site as well as the 3' region of exon 2. Taken together, the presence of a single AON that appears to affect both proximal and distal effects in splicing suggests complex splicing events.
[0064] [Diagram 36]Long sequence read analysis of splicing regulation induced by BKV-targeted lead compound AON. Long sequence read analysis of RNA transcripts from HK2 cells pretreated with scrambled AON or our lead compound AON (HYB_01, HYB_03 or HYB_11). Left: Bar graphs represent the percentage of transcripts using large T or small t donor sites in combination with fixed acceptor sites (intron-exon 2) or unspliced transcripts, showing splicing regulation by BKV-targeted AON. Right: Bar graphs represent the percentage of transcripts using truncated T or truncated T* acceptor sites in combination with fixed donor sites, showing splicing regulation by BKV-targeted AON.
[0065] [Figure 37] Schematic diagram of JC virus genome and JCV targeting AON. Part 1 (Figure 37-1): Similar to BK virus, JC virus genome encodes small t and large T antigens (early genes), as well as agnoprotein and major capsid proteins VP1, VP2 and VP3 (late genes). The viral genome also contains a non-coding region (NCCR) with origin of replication and promoter regions for transcription factor binding that drive expression of early and late genes and viral genome replication. In contrast to the extensive knowledge about BKV splicing of pre-mRNA of early and late regions, little is known about JCV splicing. Part 2 (Figure 37-2): AON sequence used to target exon-intron junction of JCV large T antigen (TAg) as shown in the top panel. Part 3 (Figure 37-3): Schematic diagram showing binding sites for AONs at exon-intron junction of JCV TAg.
[0066] [Figure 38]TAg splicing-modulating AONs reduce TAg mRNA expression levels in JCV-infected human induced pluripotent stem cell-derived astrocytes. Reduced TAg mRNA levels in hiPSC-derived astrocytes treated with scrambled AONs versus JCV-targeted AONs (cells were infected with JCV after treatment) (n=1).
[0067] [Figure 39] TAg splicing-modulating AONs reduce VP1 mRNA expression levels in JCV-infected human induced pluripotent stem cell-derived astrocytes. Reduced VP1 mRNA levels in hiPSC-derived astrocytes treated with scrambled AONs versus JCV-targeted AONs (cells were infected with JCV after treatment) (n=1).
[0068] [Diagram 40] TAg splicing-modulating AONs reduce TAg mRNA expression levels in primary human astrocytes infected with JCV. Reduced TAg mRNA levels in primary astrocytes treated with scrambled AONs versus JCV-targeted AONs (cells were infected with JCV after treatment) (n=2 biological replicates).
[0069] [Diagram 41] TAg splicing-modulating AONs reduce VP1 mRNA expression levels in primary human astrocytes infected with JCV. Reduced VP1 mRNA levels in primary astrocytes treated with scrambled AONs versus JCV-targeted AONs (cells were infected with JCV after treatment) (n=2 biological replicates).
[0070] [Diagram 42]Coverage of the BKV genome by RNA amplified during RNA-seq. Alignment of paired-end reads to the BKV genome from cells treated with scrambled control, HYB_01, HYB_03, HYB_11, HYB_14 or SAN_73 and SAN_74 allows for semi-quantitative assessment of BKV RNA expression levels. Data represent biological n=3 and were separated into expression profiles of early and late genes.
[0071] [Diagram 43] Electrophoretic analysis of TAg (pre)mRNA generated by long-read high-fidelity Phusion polymerase. Long-read high-fidelity mRNA was generated from RNA recovered from HK2 cells treated with scrambled control AONs (lane 1) or BKV-targeted AONs (i.e., HYB_01, HYB_03 or HYB_11; lanes 2-4, respectively) using Phusion polymerase and assessed by capillary electrophoresis. Data are representative of biological n=3.
[0072] [Diagram 44] Fluorescence microscopy of AON uptake in mouse kidney 24 hours after intravenous administration. Color-coded high magnification images of mouse kidney sections 24 hours after intravenous administration of 40 mg / kg HYB_01 (2'MOE without 5'6-FAM label) to C57BL / 6J mice. Nuclear staining with Hoechst reveals uptake by proximal tubule epithelial cells based on co-localization with winged bean lectin (LTL) positive cells in the kidney (proximal tubule). Left panel shows 100x magnification (10x objective, scale bar = 100 μm), whereas right panel shows 400x magnification (40x objective, scale bar = 20 μm).
[0073] [Diagram 45]Immunohistochemical staining of mouse tissues for BKV-targeted AON uptake. 24 hours after intravenous administration of 40 mg / kg HYB_01 (2'MOE without 5'6-FAM labeling) to C57BL / 6J mice, organs were excised and AON uptake was assessed immunohistochemically. After hematoxylin-eosin staining (H&E), AON scaffolds were specifically detected by anti-phosphorothioate antibody and diaminobenzidine (DAB) as peroxidase substrate to reveal HRP-labeled secondary antibody. Positive AON staining signals were visualized by color deconvolution and thresholding in ImageJ, which showed significantly lower signal in liver and no signal in heart tissue, but positive tubules with high levels of AON uptake. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0074] The term "antisense oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA), or mimetics, chimeras, analogs, and homologs thereof. The term includes antisense oligonucleotides composed of naturally occurring nucleobases, sugars, and covalent internucleoside (backbone) linkages, as well as antisense oligonucleotides with non-naturally occurring portions that function similarly. Such modified or substituted antisense oligonucleotides are often preferred over the natural forms because they have desirable properties, such as increased cellular uptake, high affinity for target nucleic acid, and high stability in the presence of nucleases (see Figure 7).
[0075] The antisense oligonucleotides described herein are preferably single-stranded antisense oligonucleotides.
[0076] The antisense oligonucleotide of the present invention also includes modified antisense oligonucleotides that have different bases at one or more nucleotide positions in the antisense oligonucleotide.For example, if the first nucleotide is adenosine, modified antisense oligonucleotides can be made that contain thymidine, guanosine or cytidine at this position.This can be done at any position of the antisense oligonucleotide.These antisense oligonucleotides are then tested using the method described herein to measure the ability to inhibit T antigen RNA.
[0077] The antisense oligonucleotide of the present invention can hybridize with the polyomavirus RNA produced when susceptible cells are infected.Therefore, the antisense oligonucleotide comprises a sequence that is the reverse complement of the (part of) sequence of the target RNA.The antisense oligonucleotide can be introduced in the form of a single-stranded, double-stranded, partially single-stranded or circular oligomeric compound.In a preferred embodiment, the antisense oligonucleotide is a single-stranded antisense oligonucleotide.
[0078] The antisense oligonucleotide can be linked to one or more other chemical structures. The other structures can be peptides or proteins, sugars, lipids or other chemical structures. The other structures can also be one or more other nucleotides. The one or more other nucleotides can perform a different function than the antisense moiety. For example, hybridization to another nuclear target sequence. The other structures can perform any one or more of several different functions. Non-limiting examples of such functions are the stability of antisense oligonucleotide, increasing bioavailability, increasing cell penetration, increasing nuclear delivery, targeting to specific cells, etc.
[0079] Once introduced into a system, the antisense oligonucleotides of the present invention can induce the action of one or more enzymes or structural proteins to result in modification of the target nucleic acid. It is known in the art that single-stranded antisense oligonucleotides that are "DNA-like" induce RNaseH, a cellular endonuclease that cleaves the RNA strand of an RNA:DNA duplex. Thus, activation of RNaseH results in cleavage of the RNA target. This is one way to increase the efficiency of antisense oligonucleotide-mediated gene expression inhibition. In embodiments, the antisense oligonucleotides of the present invention do not recruit, and are not designed to recruit, the action of RNaseH to the target RNA / antisense oligonucleotide hybrid. Similar roles have been postulated for other ribonucleases, such as RNaseIII and ribonuclease L family enzymes. The antisense oligonucleotides described herein preferably have modifications that confer nuclease resistance to the antisense oligonucleotide and the target RNA / antisense oligonucleotide hybrid. Specifically excluded from the definition of "antisense oligonucleotide" herein are ribozymes which contain internal or external "bulges" which do not hybridize to the target sequence.
[0080] The antisense oligonucleotides of the present invention comprise 12-30, preferably 17, 18, 19 or 20-30 nucleobases (i.e., about 12-30 (including 30) linked nucleosides). One of skill in the art will recognize that the present invention specifically exemplifies antisense oligonucleotides that are 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleobases in length. One of skill in the art will recognize that this specifically exemplifies antisense oligonucleotides that are 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleobases in length. Those skilled in the art will recognize that this specifically exemplifies the antisense oligonucleotide of 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleobases in length. Antisense oligonucleotides are often 18, 19, 20, 21 or 22 nucleobases in length. The antisense oligonucleotides described herein are preferably 17, 18, 19, 20, 21 or 22 nucleotides in length.
[0081] In one embodiment, the antisense oligonucleotide comprises at least 12 consecutive nucleobases of the sequence of an oligonucleotide specifically disclosed herein. Antisense oligonucleotides 12-30 nucleobases in length comprising a stretch of at least 12 consecutive nucleobases selected from within these exemplary antisense oligonucleotides are also considered to be suitable antisense oligonucleotides.
[0082] Antisense oligonucleotides comprise a sequence of nucleobases that is the reverse complement of the sequence of target RNA.Antisense oligonucleotides described herein comprise a stretch of at least 12 nucleobases, with a sequence that is the reverse complement of the sequence of at least 12 consecutive nucleobases of target RNA.The stretch is also referred to as complementary region or hybridization region.Those skilled in the art will recognize that the present invention specifically exemplifies antisense oligonucleotides with a complementary region of 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleobases.Those skilled in the art will recognize that the present invention specifically exemplifies antisense oligonucleotides with a complementary region of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleobases. Those skilled in the art will recognize that the present invention specifically exemplifies the antisense oligonucleotide with a complementary region of 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26 nucleobases in length.Antisense oligonucleotides often have a complementary region of 18, 19, 20, 21 or 22 nucleobases in length.Antisense oligonucleotides described herein preferably have a complementary region of 17, 18, 19, 20, 21 or 22 nucleobases in length.
[0083] The antisense oligonucleotide preferably has a length equivalent to the length of the complementary region.
[0084] The target sequence of the antisense oligonucleotide described herein is a part of the polyomavirus T antigen pre-mRNA. Pre-mRNA or pre-mRNA is an immature single strand of messenger ribonucleic acid (mRNA). Polyomavirus T antigen pre-mRNA is synthesized from a polyomavirus DNA template by transcription in the cell nucleus. The pre-mRNA contains one or more introns that are excised during the maturation of pre-mRNA to mRNA. The splicing process removes introns from the transcript and joins exons together. Introns are usually flanked by a donor site (the 5' end of the intron) and an acceptor site (the 3' end of the intron). Splice sites are necessary for splicing and usually contain a nearly constant sequence GU at the 5' end of the intron and a splice acceptor site with a nearly constant AG sequence at the 3' end of the intron. The GU and AG sequences and the intervening sequence are excised from the pre-mRNA. A feature of polyomavirus T antigen pre-mRNA is that it can undergo alternative splicing or not, producing at least two, and often three, four or five, differently spliced mRNAs (see FIG. 1). Viral propagation depends on the availability of viral genomes, the presence of viral proteins, the cellular machinery, and especially on the delicate interplay between the various stages and components. The splicing process of viral RNA is an important way to control the viral propagation process, affecting the level and possibly also the timing of certain products formed in cells. In the present invention, it has surprisingly been found that by directing the oligonucleotides of the present invention to the splice donor or splice acceptor sites for splicing of large T antigen mRNA, a significant effect can be obtained not only on the production of T antigen mRNA, but also on the level of capsid protein produced by infected cells and on the production of virus.
[0085] The target sequence of the antisense oligonucleotide described herein comprises the splice donor site of polyomavirus T antigen pre-mRNA, the splice acceptor site of polyomavirus T antigen pre-mRNA or a combination thereof.The target sequence usually comprises a stretch of 12 consecutive nucleobases comprising the splice donor site of polyomavirus T antigen pre-mRNA or the splice acceptor site of polyomavirus T antigen pre-mRNA.The consecutive sequence preferably comprises an intron sequence in addition to the splice donor or splice acceptor sequence.In a preferred embodiment, the consecutive sequence comprises one or two intron nucleobases adjacent to the splice donor or splice acceptor sequence. In a preferred embodiment, the contiguous sequence comprises 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28 intronic nucleobases adjacent to the splice donor or splice acceptor sequence. In a preferred embodiment, the contiguous sequence comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28 exonic nucleobases adjacent to the splice donor or splice acceptor sequence. The antisense oligonucleotide preferably comprises a sequence that is the reverse complement of the contiguous sequence of nucleobases of the target pre-mRNA. The sum of the number of nucleobases of the introns, splice sites and exons does not exceed the total number of nucleobases in the antisense oligonucleotide.
[0086] The target sequence preferably includes a splice donor or splice acceptor sequence that defines an intron that is excised to generate an mRNA encoding the large T antigen of a particular polyomavirus (see FIG. 8).
[0087] The sequences of the antisense oligonucleotides described herein contain complementarity to splice donor or splice acceptor sequences that define the intron that is excised to produce an mRNA encoding the large T antigen of a particular polyomavirus (see Figure 8).
[0088] In a preferred embodiment, the target sequence of the first oligonucleotide is a sequence in the 3' splice site target region shown below for each virus. In a preferred embodiment, the target sequence of another oligonucleotide is a sequence in the 5' splice site target region shown below for each virus. The oligonucleotides targeted to the target sequence in the region shown below contain the complementary sequence of the splice donor or splice acceptor in the sequence shown. When two or more AONs are used in the methods described herein, it is preferred that the AONs are targeted to the same viral target sequence.
[0089] [Table 1]
[0090] The first column contains an abbreviation of the virus name. The prototype sequence of the virus is shown, along with the accession code for that sequence in sequence databases. The third and fourth columns show regions in the prototype virus sequence that contain the splice donor (column 4) or splice acceptor (column 3). The AONs described herein can contain regions of complementarity to these splice donors or splice acceptors.
[0091] The antisense oligonucleotides of the present invention may modulate the splicing of T antigen pre-mRNA in infected cells. Without being bound by theory, it is believed that the antisense oligonucleotides described herein inhibit the use of the splice site that they target. The resulting reduction in large T antigen production affects the expression of capsid proteins, thereby affecting virus production (see Figures 4-6). Without being bound by theory, it is believed that the imbalance of T antigen-specific splicing products induced by the antisense oligonucleotides of the present invention has a more pronounced effect on virus propagation than the reduction of T antigen mRNA-specific mRNA by RNAi-like approaches.
[0092] In the context of the present invention, "hybridization" refers to the pairing of complementary strands of nucleic acid. In the present invention, the preferred mechanism of pairing involves hydrogen bonding, which can be Watson-Crick hydrogen bonding, Hoogsteen hydrogen bonding, or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases (nucleobases). For example, adenine and thymine are complementary nucleobases that pair by forming hydrogen bonds. Hybridization can occur in a variety of contexts. Hybridization of complementary strands usually improves as the length of the sequence increases. Specific hybridization of two strands is achieved with a continuous stretch of 12 or more complementary nucleobases. The sequence of an antisense oligonucleotide can be, but is not necessarily, 100% complementary to its target sequence to be specifically hybridizable. In addition, an antisense oligonucleotide may hybridize over one or more segments such that intervening or adjacent segments are not involved in the hybridization event. In one embodiment of the present invention, the antisense oligonucleotide of the present invention comprises at least 70% or at least 75% or at least 80% or at least 85% sequence complementarity to the target region in the target pre-mRNA.In another embodiment, the antisense oligonucleotide of the present invention comprises at least 90% sequence complementarity, or even at least 95% or at least 96% sequence complementarity to the target region in the target pre-mRNA.For example, an antisense compound in which 18 nucleobases out of 20 nucleobases of the antisense compound are complementary to the target region and therefore can specifically hybridize can represent 90 percent complementarity.When an 18-nucleotide antisense oligonucleotide has a sequence that is the reverse complement of at least 12 nucleobases of a continuous stretch of polyomavirus large T antigen pre-mRNA, the remaining 6 complementary nucleobases can be clustered with the 12 nucleobases or can be non-contiguous with the 12 nucleobases.The percent complementarity of an antisense oligonucleotide to a region of a target pre-mRNA can be routinely measured using the BLAST (basic local alignment search tool) and PowerBLAST programs (Altschulet al., J. Mol. Biol., 1990, 215, 403-410; Zhang and Madden, Genome Res., 1997, 7, 649-656) known in the art. Since the number of nucleotides is necessarily an integer, the actual percentage may not be exactly 90% or exactly 96%. The contiguous sequence preferably has no nucleotide mismatch or only one nucleotide mismatch with respect to the target nucleic acid sequence.
[0093] Antisense oligonucleotides of 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases in length are preferably at least 80% complementary to nucleotides in the region 4537-4596 or region 4881-4940 taken from NC_001538 and include at least complementarity to the splice donor or splice acceptor sequences in the respective regions, and are preferably at least 90% complementary to nucleotides 4537-4596 or 4881-4940 taken from NC_001538. The 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases are preferably complementary to a stretch of at least 12, 13, 14, 15, 16, 17, 18, 19, 30, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 consecutive nucleotides of the target pre-mRNA. In a preferred embodiment, the oligonucleotide is 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases in length and preferably comprises the sequence shown in SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:22; SEQ ID NO:23; SEQ ID NO:24; SEQ ID NO:25; SEQ ID NO:26 or SEQ ID NO:27; preferably the sequence shown in SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:6; SEQ ID NO:7; SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10; SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:22; SEQ ID NO:23; SEQ ID NO:24 or SEQ ID NO:25; preferably the sequence shown in SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:22; SEQ ID NO:23; SEQ ID NO:24 or SEQ ID NO:25.
[0094] Antisense oligonucleotides of 12-30, preferably 17, 18, 19 or 20-30 nucleobases in length are preferably at least 80% complementary to nucleotides in the region 4397-4456 or region 4741-4800 taken from NC_001699 and include at least complementarity to the splice donor or splice acceptor sequences in the respective regions, and are preferably at least 90% complementary to nucleotides 4397-4456 or region 4741-4800 taken from NC_001699. The 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases are preferably complementary to a stretch of at least 12, 13, 14, 15, 16, 17, 18, 19, 30, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 consecutive nucleotides of the target pre-mRNA.
[0095] Antisense oligonucleotides of 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases in length are preferably at least 80% complementary to nucleotides in the region 4299-4358 or region 4686-4745 taken from NC_009238 and include at least complementarity to the splice donor or splice acceptor sequences in the respective regions, and are preferably at least 90% complementary to nucleotides 4299-4358 or region 4686-4745 taken from NC_009238. The 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases are preferably complementary to a stretch of at least 12, 13, 14, 15, 16, 17, 18, 19, 30, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 consecutive nucleotides of the target pre-mRNA.
[0096] Antisense oligonucleotides of 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases in length are preferably at least 80% complementary to nucleotides in the region 4477-4536 or the region 4876-4935 taken from NC_009539 and include at least complementarity to the splice donor or splice acceptor sequences in the respective regions, and are preferably at least 90% complementary to nucleotides 4477-4536 or the region 4876-4935 taken from NC_009539. The 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases are preferably complementary to a stretch of at least 12, 13, 14, 15, 16, 17, 18, 19, 30, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 consecutive nucleotides of the target pre-mRNA.
[0097] Antisense oligonucleotides of 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases in length are preferably at least 80% complementary to nucleotides in the region 4693-4752 or region 5124-5183 taken from NC_010277 and include at least complementarity to the splice donor or splice acceptor sequences in the respective regions, and are preferably at least 90% complementary to nucleotides 4693-4752 or region 5124-5183 taken from NC_010277. The 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases are preferably complementary to a stretch of at least 12, 13, 14, 15, 16, 17, 18, 19, 30, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 consecutive nucleotides of the target pre-mRNA.
[0098] Antisense oligonucleotides of 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases in length are preferably at least 80% complementary to nucleotides in the region 4264-4323 or region 4654-4713 taken from NC_014406 and include at least complementarity to the splice donor or splice acceptor sequences in the respective regions, and are preferably at least 90% complementary to nucleotides 4264-4323 or region 4654-4713 taken from NC_014406. The 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases are preferably complementary to a stretch of at least 12, 13, 14, 15, 16, 17, 18, 19, 30, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 consecutive nucleotides of the target pre-mRNA.
[0099] Antisense oligonucleotides of 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases in length are preferably at least 80% complementary to nucleotides in the region 4272-4331 or region 4677-4736 taken from NC_014407 and include at least complementarity to the splice donor or splice acceptor sequences in the respective regions, and are preferably at least 90% complementary to nucleotides 4272-4331 or region 4677-4736 taken from NC_014407. The 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases are preferably complementary to a stretch of at least 12, 13, 14, 15, 16, 17, 18, 19, 30, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 consecutive nucleotides of the target pre-mRNA.
[0100] Antisense oligonucleotides of 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases in length are preferably at least 80% complementary to nucleotides in the region 4352-4411 or region 4765-4824 taken from NC_014361 and include at least complementarity to the splice donor or splice acceptor sequences in the respective regions, and are preferably at least 90% complementary to nucleotides 4352-4411 or region 4765-4824 taken from NC_014361. The 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases are preferably complementary to a stretch of at least 12, 13, 14, 15, 16, 17, 18, 19, 30, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 consecutive nucleotides of the target pre-mRNA.
[0101] Antisense oligonucleotides of 12-30, preferably 17, 18, 19 or 20-30 nucleobases in length are preferably at least 80% complementary to nucleotides in the region 4408-4467 or region 4760-4819 taken from NC_015150 and include at least complementarity to the splice donor or splice acceptor sequences in the respective regions, and are preferably at least 90% complementary to nucleotides 4408-4467 or region 4760-4819 taken from NC_015150. The 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases are preferably complementary to a stretch of at least 12, 13, 14, 15, 16, 17, 18, 19, 30, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 consecutive nucleotides of the target pre-mRNA.
[0102] Antisense oligonucleotides of 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases in length are preferably at least 80% complementary to nucleotides in the region 4303-4362 or region 4658-4717 taken from NC_018102 and include at least complementarity to the splice donor or splice acceptor sequences in the respective regions, and are preferably at least 90% complementary to nucleotides 4303-4362 or region 4658-4717 taken from NC_018102. The 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases are preferably complementary to a stretch of at least 12, 13, 14, 15, 16, 17, 18, 19, 30, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 consecutive nucleotides of the target pre-mRNA.
[0103] Antisense oligonucleotides of 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases in length are preferably at least 80% complementary to nucleotides in the region 4159-4218 or region 4504-4563 taken from NC_020106 and include at least complementarity to the splice donor or splice acceptor sequences in the respective regions, and are preferably at least 90% complementary to nucleotides 4159-4218 or region 4504-4563 taken from NC_020106. The 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases are preferably complementary to a stretch of at least 12, 13, 14, 15, 16, 17, 18, 19, 30, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 consecutive nucleotides of the target pre-mRNA.
[0104] Antisense oligonucleotides of 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases in length are preferably at least 80% complementary to nucleotides in the region 4392-4451 or region 4791-4850 taken from NC_020890 and include at least complementarity to the splice donor or splice acceptor sequences in the respective regions, and are preferably at least 90% complementary to nucleotides 4392-4451 or region 4791-4850 taken from NC_020890. The 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases are preferably complementary to a stretch of at least 12, 13, 14, 15, 16, 17, 18, 19, 30, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 consecutive nucleotides of the target pre-mRNA.
[0105] Antisense oligonucleotides of 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases in length are preferably at least 80% complementary to nucleotides in the region 4471-4530 or region 4859-4918 taken from NC_024118 and include at least complementarity to the splice donor or splice acceptor sequences in the respective regions, and are preferably at least 90% complementary to nucleotides 4471-4530 or region 4859-4918 taken from NC_024118. The 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases are preferably complementary to a stretch of at least 12, 13, 14, 15, 16, 17, 18, 19, 30, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 consecutive nucleotides of the target pre-mRNA.
[0106] The antisense oligonucleotides described herein are preferably selected from the group consisting of SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; SEQ ID NO:6; SEQ ID NO:7; SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10; SEQ ID NO:11; SEQ ID NO:12; SEQ ID NO:13; SEQ ID NO:14; SEQ ID NO:15; SEQ ID NO:16; SEQ ID NO:17; SEQ ID NO:18; SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:22; SEQ ID NO:23; SEQ ID NO:24; SEQ ID NO:25; SEQ ID NO:26 or SEQ ID NO:27, preferably SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:6; SEQ ID NO:7; SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:1 and preferably at least 12 contiguous nucleobases of SEQ ID NO:1;SEQ ID NO:2;SEQ ID NO:3;SEQ ID NO:4;SEQ ID NO:20;SEQ ID NO:21;SEQ ID NO:22;SEQ ID NO:23;SEQ ID NO:24 or SEQ ID NO:25, wherein the at least 12 nucleotides preferably comprise a splice donor site, a splice acceptor site or a combination thereof of the target pre-mRNA, i.e., the reverse complement of the splice donor / acceptor site of the respective polyomavirus large T antigen pre-mRNA, which reverse complement is present in the respective SEQ ID NO.
[0107] The present invention further relates to antisense oligonucleotides comprising a nucleotide sequence of at least 12 consecutive nucleobases (see Figures 3 and 10): 5'ACCUCUGAGCUACUCCAGGU3' SEQ ID NO:1; 5'ACAAACCUCUGAGCUACUCC3' SEQ ID NO:2; 5'CAGCACAAACCUCUGAGCUA3' SEQ ID NO:3; 5'UCCAUAGGUUGGCACCUAGA3' SEQ ID NO:4; 5'UGUUCCAUAGGUUGGCACCU3' SEQ ID NO:5; 5'AAACCUCUGAGCUACUCCAG3' SEQ ID NO:20; 5'GCACAAACCUCUGAGCUACU3' SEQ ID NO:21; 5'AUCAGCACAAACCUCUGAGC3' SEQ ID NO:22; 5'AAAUCAGCACAAACCUCUGA3' SEQ ID NO:23; 5'GAAAAUCAGCACAAACCUCU3' SEQ ID NO:24; 5'AGGAAAAUCAGCACAAACCU3' SEQ ID NO:25; 5'CAUAGGUUGGCACCUAUAAA3' SEQ ID NO:26 or 5'UUCCAUAGGUUGGCACCUAU3' SEQ ID NO:27.
[0108] The antisense oligonucleotides described herein are preferably selected from the group consisting of SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; SEQ ID NO:6; SEQ ID NO:7; SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10; SEQ ID NO:11; SEQ ID NO:12; SEQ ID NO:13; SEQ ID NO:14; SEQ ID NO:15; SEQ ID NO:16; SEQ ID NO:17; SEQ ID NO:18; SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:22; SEQ ID NO:23; SEQ ID NO:24; SEQ ID NO:25; SEQ ID NO:26 or SEQ ID NO:27; preferably SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:6; SEQ ID NO:7; SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO: 10;SEQ ID NO:20;SEQ ID NO:21;SEQ ID NO:22;SEQ ID NO:23;SEQ ID NO:24 or SEQ ID NO:25;preferably, SEQ ID NO:1;SEQ ID NO:2;SEQ ID NO:3;SEQ ID NO:4;SEQ ID NO:20;SEQ ID NO:21;SEQ ID NO:22;SEQ ID NO:23;SEQ ID NO:24 or SEQ ID NO:25, wherein at least 13, 14, 15, 16, 17, 18, 19 or 20 consecutive nucleobases of SEQ ID NO:1;SEQ ID NO:2;SEQ ID NO:3;SEQ ID NO:4;SEQ ID NO:20;SEQ ID NO:21;SEQ ID NO:22;SEQ ID NO:23;SEQ ID NO:24 or SEQ ID NO:25, and preferably, at least 13, 14, 15, 16, 17, 18, 19 or 20 nucleotides of each of them comprise the reverse complement of the splice donor site, splice acceptor site or combination thereof of target pre-mRNA. The nucleobases shown herein can be replaced by different nucleobases with the same base pairing activity, not necessarily in amount, but in kind. An example of such a replacement is a thymidine base as a replacement for uracil. Other nucleobases can be used instead of the replacement with the same kind of base pairing activity.
[0109] Another alternative is the base that pairs with any base.An example of a base is inosine.Such a base does not usually add specificity to oligonucleotide compared to the base that pairs with the appropriate base in target RNA.Oligonucleotides can accept this to some extent, as known to those skilled in the art.If the same specificity is desired, additional selective bases can be added to oligonucleotide, for example, but not limited to, one additional selective base to replace each of inosine or other non-selective bases.
[0110] The antisense oligonucleotide preferably comprises at least 12 consecutive nucleobases of the nucleotide sequence shown above (see FIG. 9):
[0111] [Table 2]
[0112] In one embodiment, the antisense oligonucleotides described herein contain at least one backbone modification. In one embodiment, the antisense oligonucleotides contain phosphorothioate modifications. Phosphorothioate (PS) modifications substitute sulfur atoms for non-bridging oxygens in the phosphate backbone of the oligo. This modification renders the internucleotide linkages resistant to nuclease degradation. Phosphorothioate bonds can be introduced between the last 3-5 nucleotides at the 5' or 3' end of the oligo to inhibit exonuclease degradation (see Figure 7). Similarly, including phosphorothioate bonds throughout the oligo also helps reduce endonuclease attack (see Figure 3).
[0113] In another embodiment, antisense oligonucleotide comprises morpholino (phosphorodiamidate morpholino) modification.Morpholino has standard nucleobase, but the bases are linked to each other by phosphorodiamidate group instead of phosphate, and the morpholino ring is connected.Morpholino does not cause the degradation of their target RNA molecule.
[0114] In one embodiment, the antisense oligonucleotide comprises at least one sugar modification on the 2' carbon of the ribose moiety of the nucleoside. In one embodiment, the antisense oligonucleotide comprises at least one 2' sugar modification. A review of sugar modifications for antisense purposes is provided by Prakash (2011; Chem. Biodivers. Sept. 8(9):1616-1641. Doi 10.1002 / cbdv.201100081). As shown in Figure 7, the preferred 2' sugar modification is a 2'-alkoxy or 2'-alkoxyalkoxy modification, more preferably 2'-methoxyethoxy. Preferred modifications are 2'-O-methyl (2'-O-Me), 2'-O-methoxyethyl (2'-MOE), 2'-S-constrained ethyl (2'-cEt) and locked nucleic acid (LNA).
[0115] Other modifications include peptide nucleic acids (PNAs). In some embodiments, all positions in a given antisense oligonucleotide are uniformly modified. In other embodiments, some positions in a given antisense oligonucleotide are not uniformly modified. Indeed, more than one of the above modifications may be incorporated into a single antisense oligonucleotide, or even into a single nucleoside within an antisense oligonucleotide. The present invention also includes antisense oligonucleotides that are chimeric antisense oligonucleotides. Chimeric antisense oligonucleotides are antisense oligonucleotides that contain two or more chemically distinct regions, each of which is composed of at least one nucleotide. These antisense oligonucleotides contain at least one region that has been modified to confer to the antisense oligonucleotide high resistance to nuclease degradation, increased cellular uptake, and / or high binding affinity to the target nucleic acid.
[0116] Antisense oligonucleotides can serve as substrates for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. Such a possibility is often mediated by the inclusion of a region within the antisense oligonucleotide. Such antisense oligonucleotides are also called "gapmers". Gapmers are chimeric antisense oligonucleotides that usually contain a block of deoxyribonucleotide monomers in the middle that is long enough to induce RNaseH cleavage. Efficient RNase cleavage requires a stretch of four or more deoxyribonucleotides. Usually, such a stretch has nine or more deoxyribonucleotides. In the present invention, it is preferred that antisense oligonucleotides do not contain a region that can serve as substrates for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids.
[0117] The present antisense oligonucleotides preferably contain modified nucleotides, such as phosphorothioate modified nucleobases and / or 2' sugar modifications, which provide resistance to accidental degradation by nucleases. As shown in Figure 7, the preferred 2' sugar modifications are 2'-alkoxy or 2'-alkoxyalkoxy modifications, more preferably 2'-methoxyethoxy. Preferred 2' sugar modifications include 2'-O-methyl (2'-O-Me), 2'-O-methoxyethyl (2'-MOE), 2'-S-constrained ethyl (2'-cEt) and locked nucleic acid (LNA). The backbone may contain phosphorothioates throughout. Other configurations of antisense oligonucleotides are also encompassed by the present invention. The antisense oligonucleotides preferably contain modified nucleotides, such as phosphorothioate modified nucleobases and / or 2' sugar modifications, which provide resistance to accidental degradation of the target RNA by nucleases. Such antisense oligonucleotides are within the scope of the present invention. Thus, the oligonucleotides disclosed herein preferably have a region that confers nuclease resistance to the target RNA: the duplex formed by the antisense oligonucleotide and the target RNA is not susceptible to the action of RNase H.
[0118] In a preferred embodiment, the antisense oligonucleotide comprises one or more nucleobases with a modified polymer backbone. The modified polymer backbone is preferably a modified backbone, as described elsewhere herein. In a preferred embodiment, the modified polymer backbone comprises 2'-O-methyl (2'-O-Me), 2'-O-methoxyethyl (2'-MOE), 2'-S-constrained ethyl (2'-cEt), locked nucleic acid (LNA), peptide nucleic acid (PNA) or morpholino (PMO) nucleotides. In a preferred embodiment, all of the nucleotides in the modified polymer backbone comprise a modified sugar moiety, preferably at the 2' carbon. In a preferred embodiment, the phosphate group linking two nucleotides is modified to a phosphorothioate group. Preferably, all of the phosphodiester linkages in the modified polymer backbone are phosphorothioate linkages.
[0119] Human polyomaviruses can be divided into several genera, called alpha, beta and delta (Helle, F. et. al., Viruses, 2017). In a preferred embodiment, the polyomavirus is an alphavirus or a betavirus, preferably a betavirus. Some human polyomaviruses are listed in the table below herein. In a preferred embodiment, the polyomavirus is a BK polyomavirus (or a BK virus, also referred to herein as BKPyV or BKV), a JC polyomavirus (or a JC virus, also referred to herein as JCV) or a Merkel cell polyomavirus (MC polyomavirus, MC virus, or also referred to herein as MCV). In a particularly preferred embodiment, the polyomavirus is a BK virus or a JC virus, preferably a BK virus.
[0120] [Table 3]
[0121] The present invention also provides a method of inhibiting polyomavirus replication in a cell, comprising providing an antisense oligonucleotide as described herein to a cell infected with said polyomavirus. The antisense oligonucleotide is preferably an oligonucleotide that targets the polyomavirus of the infection (see FIG. 3). The cell is preferably a cell susceptible to polyomavirus replication. When the cell is a cell in an animal, such as a human, the animal is preferably a permissive host, i.e., a host that allows the virus to circumvent the host's defenses and replicate. In the case of polyomaviruses, such as BK and JC viruses, replication is often first detected by detecting the virus in the animal's urine (uremia). Later, if the infection persists, the virus can also be detected in the animal's serum (viremia). Most humans encounter BK and JC viruses during childhood, causing mild illness. However, when reactivated or acquired in an immunocompromised host, BK and JC viruses are involved in several human clinical disease states. BK is most commonly associated with renal disorders such as ureteral stenosis, hemorrhagic cystitis, and nephropathy (Leploeg, MD et. al., Clinical Infectious Diseases, 2001; Helle, F. et. al., Viruses, 2017). Host susceptibility or tolerance can be induced by compromising the host's immune system. A variety of circumstances can temporarily or permanently reduce the host's immunity. Immunodeficiency (or immune deficiency) is a state in which the immune system has impaired or no ability to fight infections and cancer. Most cases of immunodeficiency are acquired ("secondary") and result from external factors that affect the patient's immune system. Examples of these external factors include HIV infection, extremes of age, and environmental factors such as nutrition.Immunosuppression can also be induced by some drugs (e.g., glucocorticoids, cytostatics, antibodies, and immunophilins (e.g., calcineurin inhibitors, belatacept (an immunoglobulin-like molecule with the extracellular domain of CTLA-4) and compounds that affect similar molecules). This can be a desired effect, such as in organ transplant surgery as an anti-rejection measure, and in patients suffering from an overactive immune system, such as in autoimmune diseases. However, occasionally this desired effect has the additional effect of reducing the ability of the individual to fight viral infections, such as polyomavirus infections. People with any kind of immune deficiency are said to be immunocompromised. Immunocompromised people can be particularly susceptible to opportunistic infections in addition to the usual infections that anyone can get.
[0122] In one embodiment, the present invention provides a method for preparing a graft for transplantation, characterized in that donor cells, preferably donor kidney cells, are provided with antisense oligonucleotides as described herein. The antisense oligonucleotides are preferably oligonucleotides that target the polyomavirus that replicates in graft cells. In the case of kidney grafts or renal cell grafts, the polyomavirus is preferably BK virus, JC virus or MC virus specific oligonucleotides. The cells of the graft treated in this way are less susceptible to the replication of the polyomavirus for which the antisense oligonucleotide is specific. This increases the success rate of transplantation. This makes it easier to manage the transplant recipient. One way to manage opportunistic polyomavirus replication in transplant recipients and other drug-induced immunosuppression in patients is to reduce the administration of immunosuppressive drugs, which allows the immune system to recover to a degree that reduces viral infection and / or replication. When the graft is prepared as described herein, polyomavirus infection / replication in the patient is less frequent and often less severe than in patients who receive untreated grafts.The graft recipient is preferably administered one or more additional doses of antisense oligonucleotides when desired.The present invention also provides a method for treating polyomavirus infection in a subject, comprising administering the antisense oligonucleotides described herein to an individual in need thereof.The individual is preferably an immunocompromised individual.
[0123] The graft is preferably an allograft or a xenograft. The recipient of such a graft is often treated with immunosuppressive drugs to extend the survival time of the graft or to reduce the incidence and / or severity of the host-versus-graft effect. Currently, many tissues can be transplanted. When transplanting cells or organs from another genetically non-identical human or non-human animal, the host-versus-graft effect is often at high risk. Grafts include lungs, hearts, heart valves, kidneys, liver, pancreas, intestines, thymus and bone marrow. Polyomaviruses have been detected in the plasma of up to 3% of these patients who received immunosuppression after organ transplantation (De Vlaminck, I. et.al., Cell, 2013). The graft preferably includes kidneys or renal cells. The individual is preferably a recipient of a kidney transplant or a renal cell transplant.
[0124] The antisense oligonucleotide preferably confers resistance to RNase H to a duplex between the oligonucleotide and a target RNA. The antisense oligonucleotide preferably comprises a sequence which is the reverse complement of a contiguous stretch of at least 12, preferably at least 17, nucleobases of RNA that may be present in human kidney cells, preferably of a human virus capable of replicating in human kidney cells, preferably of a polyoma virus. In one embodiment, the invention provides an antisense oligonucleotide of 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases in length comprising a sequence which is the reverse complement of a contiguous stretch of at least 12 nucleobases of polyomavirus T antigen pre-mRNA, which antisense oligonucleotide is capable of modulating splicing of said T antigen pre-mRNA in a cell, which antisense oligonucleotide comprises at least 12 contiguous nucleobases of SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; SEQ ID NO:6; SEQ ID NO:7; SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10; SEQ ID NO:11; SEQ ID NO:12; SEQ ID NO:13; SEQ ID NO:14; SEQ ID NO:15; SEQ ID NO:16; SEQ ID NO:17; SEQ ID NO:18; SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:22; SEQ ID NO:23; SEQ ID NO:24; SEQ ID NO:25; SEQ ID NO:26 or SEQ ID NO:27. Further provided is an antisense oligonucleotide comprising at least 12 contiguous nucleic acid bases of SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; SEQ ID NO:6; SEQ ID NO:7; SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10; SEQ ID NO:11; SEQ ID NO:12; SEQ ID NO:13; SEQ ID NO:14; SEQ ID NO:15; SEQ ID NO:16; SEQ ID NO:17; SEQ ID NO:18; SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:22; SEQ ID NO:23; SEQ ID NO:24; SEQ ID NO:25; SEQ ID NO:26 or SEQ ID NO:27, wherein the at least 12 nucleotides comprise the reverse complement of the splice donor or splice acceptor sequence of the respective polyomavirus large T antigen pre-mRNA.
[0125] The antisense oligonucleotides described herein preferably contain modifications that make the mRNA-oligonucleotide duplex resistant to the action of RNase H. Preferably, they contain at least one nucleobase with a modified polymer backbone, preferably 2'-O-methyl (2'-O-Me), 2'-O-methoxyethyl (2'-MOE), 2'-S-constrained ethyl (2'-cEt), locked nucleic acid (LNA), peptide nucleic acid (PNA) or morpholino (PMO) nucleotide. Preferably, all of the nucleobases contain a modified polymer backbone, preferably 2'-O-methyl (2'-O-Me), 2'-O-methoxyethyl (2'-MOE), 2'-S-constrained ethyl (2'-cEt), locked nucleic acid (LNA), peptide nucleic acid (PNA) or morpholino (PMO) nucleotide.
[0126] In a preferred embodiment, the antisense oligonucleotide comprises at least 17, preferably at least 18, 19, preferably at least 20 contiguous nucleobases of SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; SEQ ID NO:6; SEQ ID NO:7; SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10; SEQ ID NO:11; SEQ ID NO:12; SEQ ID NO:13; SEQ ID NO:14; SEQ ID NO:15; SEQ ID NO:16; SEQ ID NO:17; SEQ ID NO:18; SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:22; SEQ ID NO:23; SEQ ID NO:24; SEQ ID NO:25; SEQ ID NO:26 or SEQ ID NO:27, or a combination of SEQ ID NO:1; Sequence number 2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; SEQ ID NO:6; SEQ ID NO:7; SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10; SEQ ID NO:11; SEQ ID NO:12; SEQ ID NO:13; SEQ ID NO:14; SEQ ID NO:15; SEQ ID NO:16; SEQ ID NO:17; SEQ ID NO:18; SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:22; SEQ ID NO:23; SEQ ID NO:24; SEQ ID NO:25; SEQ ID NO:26 or SEQ ID NO:27, with at least 17, preferably at least 18, 19, preferably at least 20 consecutive nucleic acid bases, with one mismatch, which is not the first or last nucleotide of the contiguous stretch.
[0127] Also provided is a method of inhibiting polyomavirus replication in a cell, comprising providing the antisense oligonucleotide to a cell infected with said polyomavirus.Also provided is a method of preparing a graft for transplantation, comprising providing the antisense oligonucleotide to a donor cell, preferably a donor kidney cell.
[0128] Further provided is a method of treating a polyomavirus infection in a subject, comprising administering to an individual in need thereof an antisense oligonucleotide as described herein, said individual being an immunocompromised individual, said individual being preferably a kidney or renal cell transplant recipient.
[0129] Also provided is a method of administering an antisense oligonucleotide to an individual for hybridization to a complementary RNA sequence in renal cells of the individual, the method being characterized in that the antisense oligonucleotide is an oligonucleotide described herein.
[0130] Further provided is an antisense oligonucleotide comprising a modification which renders the duplex between the antisense oligonucleotide and the target mRNA resistant to the action of RNase, the antisense oligonucleotide comprising the sequence of SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; SEQ ID NO:6; SEQ ID NO:7; SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10; SEQ ID NO:11; SEQ ID NO:12; SEQ ID NO:13; SEQ ID NO:14; SEQ ID NO:15; SEQ ID NO:16; SEQ ID NO:17; SEQ ID NO:18; SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:22; SEQ ID NO:23; SEQ ID NO:24; SEQ ID NO:25; SEQ ID NO:26 or SEQ ID NO:27, with no mismatches or with one or two mismatches.
[0131] It has been observed that the oligonucleotides described herein are efficiently delivered to and taken up by appropriate renal cells when administered to animals. The method of administration is preferably intravenous (IV) administration. For polyomaviruses that can cross the blood-brain barrier and enter the central nervous system (CNS), such as JC virus, it is possible to administer antisense oligonucleotides to the CNS. Various methods are known in the art. For antisense oligonucleotide-mediated treatment of JC virus infection, CNS intrathecal delivery is preferred. JC virus infection can also be addressed by IV delivery, since it is believed that JC virus often first infects via the tonsils or gastrointestinal tract, and then spreads to other organs (such as, but not limited to, the tubular epithelial cells of the kidney) where it may remain latent or continue to replicate, shedding viral particles into urine and brain.
[0132] The antisense oligonucleotide preferably does not have the following sequence: 5'-CACAAACCTCTGAGCTA; 5'-AACCUCUGAACUAUUCCAUGU; 5'-ACCUCUGAACUAUUCCAUGUA; 5'-TTCATCTGTTCCATAGGTTGGCACCTA; or 5'-TTCCATAGGTTGGCACCTAAAAAAAAA, or an alternative thereof, wherein one or more thymidines are not uracils or vice versa.
[0133] For purposes of clarity and brevity of description, features are described herein as part of the same or separate embodiments; however, it will be recognized that the scope of the invention may include embodiments having all or a partial combination of the described features. EXAMPLES
[0134] [Example 1] (material and method) (Accessions used for phylogenetic analysis) The complete genome sequences of BK polyomavirus isolates were downloaded from the publicly available NCBI database. From these records, only isolates with reported complete genomes were used for splice site conservation in TAg. The Dunlop strain was used as the reference genome. Isolates "MM" and "FNL-9" were removed because they had large deletions in introns or overlaps that partially matched the acceptor splice site, respectively. Accession numbers for the 245 unique genome sequences are provided below: AB211369.1; AB211370.1; AB211371.1; AB211372.1; AB211373.1; AB211374.1; AB211375.1; AB211376.1; AB211377.1; AB211378.1; AB211379.1; AB211381.1; AB211382.1; AB211383.1; AB211384.1; AB211385.1; AB211386.1; AB211387.1; AB211388.1; AB211389.1; AB211390.1; AB211391.1; AB213487.1; AB217917.1; AB217918.1; AB217919.1; AB217920.1; AB217921.1; AB260028.1; AB260029.1; AB260032.1; AB260033.1; AB263912.1; AB263913.1; AB263914.1; AB263915.1; AB263916.1; AB263917.1; AB263918.1; AB263921.1; AB263922.1; AB263923.1; AB263924.1; AB263925.1; AB263926.1; AB263927.1; AB263928.1; AB263929.1; AB263930.1; AB263932.1; AB263934.1; AB263935.1; AB263936.1; AB263938.1; AB269825.1; AB269826.1; AB269827.1; AB269828.<h2 style=";text-align:left;direction:ltr">1; AB269829.1; AB269830.1; AB269831.1; AB269832.1; AB269834.1; AB269836.1; AB269837.1; AB269838.1; AB269840.1; AB269841.1; AB269842.1; AB269843.1; AB269844.1; AB269845.1; AB269846.1; AB269847.1; AB269848.1; AB269849.1; AB269850.1; AB269851.1; AB269852.1; AB269853.1; AB269854.1; AB269855.1; AB269856.1; AB269857.1; AB269858.1; AB269859.1; AB269860.1; AB269861.1; AB269862.1; AB269863.1; AB269864.1; AB269865.1; AB269866.1; AB269867.1; AB269868.1; AB269869.1; AB298941.1; AB298942.1; AB298945.1; AB298946.1; AB298947.1; AB301086.1; AB301087.1; AB301089.1; AB301090.1; AB301091.1; AB301092.1; AB301093.1; AB301094.1; AB301095.1; AB301096.1; AB301097.1; AB301099.1; AB301100.1; AB301101.1; AB365130.1; AB365132.1; AB365133.1; AB365134.1; AB365136.1; AB365137.1; AB365138.1; AB365139.1; AB365140.1; AB365141.1; AB365142.1; AB365144.1; AB365145.1; AB365146.1; AB365148.1; AB365149.1; AB365150.1; AB365151.1; AB365153.1; AB365154.1; AB365156.1; AB365157.1; AB365158.1; AB365159.1; AB365160.1; AB365162.<h2 style=";text-align:left;direction:ltr">1; AB365164.1; AB365165.1; AB365166.1; AB365167.1; AB365168.1; AB365170.1; AB365173.1; AB365174.1; AB365175.1; AB365176.1; AB365178.1; AB369087.1; AB369088.1; AB369089.1; AB369090.1; AB369092.1; AB369093.1; AB369094.1; AB369095.1; AB369096.1; AB369097.1; AB369098.1; AB369099.1; AB369101.1; AB464953.1; AB464954.1; AB464956.1; AB464957.1; AB464958.1; AB464960.1; AB464961.1; AB464962.1; AB485695.1; AB485696.1; AB485697.1; AB485698.1; AB485699.1; AB485700.1; AB485701.1; AB485703.1; AB485704.1; AB485707.1; AB485709.1; AB485710.1; AB485711.1; AB485712.1; AY628224.1; AY628225.1; AY628226.1; AY628227.1; AY628228.1; AY628229.1; AY628230.1; AY628231.1; AY628232.1; AY628233.1; AY628234.1; AY628235.1; AY628236.1; AY628237.1; AY628238.1; DQ305492.1; EF376992.1; FR720308.1; FR720309.1; FR720310.1; FR720311.1; FR720312.1; FR720313.1; FR720315.1; FR720317.1; FR720318.1; FR720320.1; FR720321.1; JF894228.1; JN192431.1; JN192432.1; JN192433.1; JN192435.1; JN192437.1; JN192438.1; JN192439.1; JN192440.KF055892.1; KF055893.1; KP412983.1; KP984526.1; KY114802.1; KY114803.1; KY132094.1; KY487998.1; LC029413.1; LC309239.1; LC309240.1; LT960370.1; M23122.1; V01108.1. .
[0135] Similarly, the complete genome sequences for 13 different prototype human polyomaviruses were downloaded, with the following accession numbers: NC_001538; NC_001699; NC_009238; NC_009539; NC_010277; NC_014406; NC_014407; NC_014361; NC_015150; NC_018102; NC_020106; NC_020890; NC_024118.
[0136] (Conservation of the splice site of the large T antigen) The whole genome nucleotide sequences of all reference human polyomaviruses were downloaded from the NCBI website (https: / / www.ncbi.nlm.nih.gov / nuccore) on February 20, 2018 and aligned using WebPrank (available online at: https: / / www.ebi.ac.uk / goldman-srv / webprank / ) with default settings. A UPGMA phylogenetic tree was constructed and sequence logos were generated for all splice sites to show conservation among different human polyomaviruses. All downloaded refseq accession numbers are also listed below.
[0137] Reference sequences: NC_001538, NC_001699, NC_009238, NC_009539, NC_010277, NC_014406, NC_014407, NC_014361, NC_015150, NC_018102, NC_020106, NC_020890, NC_024118
[0138] The whole genome nucleotide sequences of all human polyomavirus isolates were downloaded from the NCBI website on February 20, 2018. The whole gene sequences of large T antigen were retrieved only from the above unique genome sequences and aligned using WebPrank with default settings. Sequence logos were generated for all splice sites in large T antigen to show conservation within and between different human polyomaviruses.
[0139] All accession numbers downloaded are listed below: <h2 style=";text-align:left;direction:ltr">BKPyV: AB211369.1, AB211370.1, AB211371.1, AB211372.1, AB211373.1, AB211374.1, AB211375.1, AB211376.1, AB211377.1, AB211378.1, AB211379.1, AB211380.1, AB211381.1, AB211382.1, AB211383.1, AB211384.1, AB211385.1, AB211386.1, AB211387.1, AB211388.1, AB211389.1, AB211390.1, AB211391.1, AB213487.1, AB217917.1, AB217918.1, AB217919.1, AB217920.1, AB217921.1, AB260028.1, AB260029.1, AB260030.1, AB260031.1, AB260032.1, AB260033.1, AB260034.1, AB263912.1, AB263913.1, AB263914.1, AB263915.1, AB263916.1, AB263917.1, AB263918.1, AB263919.1, AB263920.1, AB263921.1, AB263922.1, AB263923.1, AB263924.1, AB263925.1, AB263926.1, AB263927.1, AB263928.1, AB263929.1, AB263930.1, AB263931.1, AB263932.1, AB263933.1, AB263934.1, AB263935.1, AB263936.1, AB263937.1, AB263938.1, AB269822.1, AB269823.1, AB269824.1, AB269825.1, AB269826.1, AB269827.1, AB269828.1, AB269829.1, AB269830.1, AB269831.1, AB269832.1, AB269833.1, AB269834.1, AB269835.1, AB269836.1, AB269837.1, AB269838.1, AB269839.1, AB269840.1, AB269841.<h2 style=";text-align:left;direction:ltr">1, AB269842.1, AB269843.1, AB269844.1, AB269845.1, AB269846.1, AB269847.1, AB269848.1, AB269849.1, AB269850.1, AB269851.1, AB269852.1, AB269853.1, AB269854.1, AB269855.1, AB269856.1, AB269857.1, AB269858.1, AB269859.1, AB269860.1, AB269861.1, AB269862.1, AB269863.1, AB269864.1, AB269865.1, AB269866.1, AB269867.1, AB269868.1, AB269869.1, AB298940.1, AB298941.1, AB298942.1, AB298943.1, AB298944.1, AB298945.1, AB298946.1, AB298947.1, AB301086.1, AB301087.1, AB301088.1, AB301089.1, AB301090.1, AB301091.1, AB301092.1, AB301093.1, AB301094.1, AB301095.1, AB301096.1, AB301097.1, AB301098.1, AB301099.1, AB301100.1, AB301101.1, AB301102.1, AB301103.1, AB365130.1, AB365131.1, AB365132.1, AB365133.1, AB365134.1, AB365135.1, AB365136.1, AB365137.1, AB365138.1, AB365139.1, AB365140.1, AB365141.1, AB365142.1, AB365143.1, AB365144.1, AB365145.1, AB365146.1, AB365147.1, AB365148.1, AB365149.1, AB365150.1, AB365151.1, AB365152.1, AB365153.1, AB365154.1, AB365155.1, AB365156.1, AB365157.1, AB365158.<h2 style=";text-align:left;direction:ltr">1, AB365159.1, AB365160.1, AB365161.1, AB365162.1, AB365163.1, AB365164.1, AB365165.1, AB365166.1, AB365167.1, AB365168.1, AB365169.1, AB365170.1, AB365171.1, AB365172.1, AB365173.1, AB365174.1, AB365175.1, AB365176.1, AB365177.1, AB365178.1, AB369087.1, AB369088.1, AB369089.1, AB369090.1, AB369091.1, AB369092.1, AB369093.1, AB369094.1, AB369095.1, AB369096.1, AB369097.1, AB369098.1, AB369099.1, AB369100.1, AB369101.1, AB464953.1, AB464954.1, AB464955.1, AB464956.1, AB464957.1, AB464958.1, AB464959.1, AB464960.1, AB464961, AB485702.1, AB485703.1, AB485704.1, AB485705.1, AB485706.1, AB485707.1, AB485708.1, AB485709.1, AB485710.1, AB485711,1 AY628224.1, AY628225.1, AY628226.1, AY628227.1, AY628228.1, AY628229.1, AY628230.1, AY628231.1, AY628232.1, AY628233.1, AY628234.1, AY628235.1, AY628236.1, AY628237.1, AY628238.1, DQ305492.1, EF376992.1, FR720308.<h2 style=";text-align:left;direction:ltr">1, FR720309.1, FR720310.1, FR720311.1, FR720312.1, FR720313.1, FR720314.1, FR720315.1, FR720316.1, FR720317.1, FR720318.1, FR720319.1, FR720320.1, FR720321.1, FR720322.1, FR720323.1, JF894228.1, JN192431.1, JN192432.1, JN192433.1, JN192434.1, JN192435.1, JN192436.1, JN192437.1, JN192438.1, JN192439.1, JN192440.1, JN192441.1, JQ713822.1, KF055891.1, KF055892.1, KF055893.1, KP412983.1, KP984526.1, KY114802.1, KY114803.1, KY132094.1, KY487998.1, LC029411.1, LC029412.1, LC029413.1, LC029414.1, LC309239.1, LC309240.1, LT934539.1, LT960370.1, M23122.1, MF627830.1, MF627831.1, V01108.1, V01109.1.<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0140] <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">JCPyV:AB038249.1, AB038250.1, AB038251.1, AB038252.1, AB038253.1, AB038254.1, AB038255.1, AB048545.1, AB048546.1, AB048547.1, AB048548.1, AB048549.1, AB048550.1, AB048551.1, AB048552.1, AB048553.1, AB048554.1, AB048555.1, AB048556.1, AB048557.1, AB048558.1, AB048559.1, AB048560.1, AB048561.1, AB048562.1, AB048563.1, AB048564.1, AB048565.1, AB048566.1, AB048567.1, AB048568.1, AB048569.1, AB048570.1, AB048571.1, AB048572.1, AB048573.1, AB048574.1, AB048575.1, AB048576.1, AB048577.1, AB048578.1, AB048579.1, AB048580.1, AB048581.1, AB048582.1, AB074575.1, AB074576.1, AB074577.1, AB074578.1, AB074579.1, AB074580.1, AB074581.1, AB074582.1, AB074583.1, AB074584.1, AB074585.1, AB074586.1, AB074587.1, AB074588.1, AB074589.1, AB074590.1, AB074591.1, AB077855.1, AB077856.1, AB077857.1, AB077858.1, AB077859.1, AB077860.1, AB077861.1, AB077862.1, AB077863.1, AB077864.1, AB077865.1, AB077866.1, AB077867.1, AB077868.1, AB077869.1, AB077870.1, AB077871.1, AB077872.1, AB077873.1, AB077874.1, AB077875.1, AB077876.1, AB077877.1, AB077878.1, AB077879.1, AB081005.1, AB081006.1, AB081007.1, AB081008.1, AB081009.1, AB081010.1, AB081011.1, AB081012.1, AB081013.1, AB081014.1, AB081015.1, AB081016.1, AB081017.1, AB081018.1, AB081019.1, AB081020.1, AB081021.1, AB081022.1, AB081023.1, AB081024.1, AB081025.1, AB081026.1, AB081027.1, AB081028.1, AB081029.1, AB081030.1, AB081600.1, AB081601.1, AB081602.1, AB081603.1, AB081604.1, AB081605.1, AB081606.1, AB081607.1, AB081608.1, AB081609.1, AB081610.1, AB081611.1, AB081612.1, AB081613.1, AB081614.1, AB081615.1, AB081616.1, AB081617.1, AB081618.1, AB081654.1, AB092578.1, AB092579.1, AB092580.1, AB092581.1, AB092582.1, AB092583.1, AB092584.1, AB092585.1, AB092586.1, AB092587.1, AB103387.1, AB103402.1, AB103403.1, AB103404.1, AB103405.1, AB103406.1, AB103407.1, AB103408.1, AB103409.1, AB103410.1, AB103411.1, AB103412.1, AB103413.1, AB103414.1, AB103415.1, AB103416.1, AB103417.1, AB103418.1, AB103419.1, AB103420.1, AB103421.1, AB103422.1, AB103423.1, AB104487.1, AB113118.1, AB113119.1, AB113120.1, AB113121.1, AB113122.1, AB113123.1, AB113124.1, AB113125.1, AB113126.1, AB113127.1, AB113128.1, AB113129.1, AB113130.1, AB113131.1, AB113132.1, AB113133.1, AB113134.1, AB113135.1, AB113136.1, AB113137.1, AB113138.1, AB113139.1, AB113140.1, AB113141.1, AB113142.1, AB113143.1, AB113144.1, AB113145.1, AB113216.1, AB113217.1, AB118231.1, AB118232.1, AB118233.1, AB118234.1, AB118235.1, AB118651.1, AB118652.1, AB118653.1, AB118654.1, AB118655.1, AB118656.1, AB118657.1, AB118658.1, AB118659.1, AB126981.1, AB126982.1, AB126983.1, AB126984.1, AB126985.1, AB126986.1, AB126987.1, AB126988.1, AB126989.1, AB126990.1, AB126991.1, AB126992.1, AB126993.1, AB126994.1, AB126995.1, AB126996.1, AB126997.1, AB126998.1, AB126999.1, AB127000.1, AB127001.1, AB127002.1, AB127003.1, AB127004.1, AB127005.1, AB127006.1, AB127007.1, AB127008.1, AB127009.1, AB127010.1, AB127011.1, AB127012.1, AB127013.1, AB127014.1, AB127015.1, AB127016.1, AB127017.1, AB127018.<h2 style=";text-align:left;direction:ltr">1, AB127019.1, AB127020.1, AB127021.1, AB127022.1, AB127023.1, AB127024.1, AB127025.1, AB127026.1, AB127027.1, AB127342.1, AB127343.2, AB127344.1, AB127345.2, AB127346.1, AB127347.1, AB127348.1, AB127349.1, AB127350.2, AB127351.2, AB127352.1, AB127353.1, AB183152.1, AB195639.1, AB195640.1, AB198940.1, AB198941.1, AB198942.1, AB198943.1, AB198944.1, AB198945.1, AB198946.1, AB198947.1, AB198948.1, AB198949.1, AB198950.1, AB198951.1, AB198952.1, AB198953.1, AB198954.1, AB220939.1, AB220940.1, AB220941.1, AB220942.1, AB220943.1, AB262396.1, AB262397.1, AB262398.1, AB262399.1, AB262400.1, AB262401.1, AB262402.1, AB262403.1, AB262404.1, AB262405.1, AB262406.1, AB262407.1, AB262408.1, AB262409.1, AB262410.1, AB262411.1, AB262412.1, AB262413.1, AB362351.1, AB362352.1, AB362353.1, AB362354.1, AB362355.1, AB362356.1, AB362357.1, AB362358.1, AB362359.1, AB362360.1, AB362361.1, AB362362.1, AB362363.1, AB362364.1, AB362365.1, AB362366.1, AB372036.1, AB372037.1, AB372038.1, AF030085.1, AF295731.<h2 style=";text-align:left;direction:ltr">1, AF295732.1, AF300945.1, AF300946.1, AF300947.1, AF300948.1, AF300949.1, AF300950.1, AF300951.1, AF300952.1, AF300953.1, AF300954.1, AF300955.1, AF300956.1, AF300957.1, AF300958.1, AF300959.1, AF300960.1, AF300961.1, AF300962.1, AF300963.1, AF300964.1, AF300965.1, AF300966.1, AF300967.1, AF363830.1, AF363831.1, AF363832.1, AF363833.1, AF363834.1, AY121907.1, AY121908.1, AY121909.1, AY121910.1, AY121911.1, AY121912.1, AY121913.1, AY121914.1, AY121915.1, AY328376.1, AY342299.1, AY349147.1, AY356539.1, AY364314.1, AY366359.1, AY373463.1, AY376828.1, AY376829.1, AY376830.1, AY376831.1, AY378084.1, AY378085.1, AY378086.1, AY378087.1, AY382184.1, AY382185.1, AY382186.1, AY382187.1, AY382188.1, AY386373.1, AY386374.1, AY386375.1, AY386376.1, AY386377.1, AY386378.1, AY536239.1, AY536240.1, AY536241.1, AY536242.1, AY536243.1, DQ875211.1, DQ875212.1, EU835194.1, JF424834.1, JF424835.1, JF424836.1, JF424837.1, JF424838.1, JF424839.1, JF424840.1, JF424841.1, JF424842.1, JF424843.1, JF424844.<h2 style=";text-align:left;direction:ltr">1, JF424845.1, JF424846.1, JF424847.1, JF424848.1, JF424849.1, JF424850.1, JF424851.1, JF424852.1, JF424853.1, JF424854.1, JF424855.1, JF424856.1, JF424857.1, JF424858.1, JF424859.1, JF424860.1, JF424861.1, JF424862.1, JF424863.1, JF424864.1, JF424865.1, JF424866.1, JF424867.1, JF424868.1, JF424869.1, JF424870.1, JF424871.1, JF424872.1, JF424873.1, JF424874.1, JF424875.1, JF424876.1, JF424877.1, JF424878.1, JF424879.1, JF424880.1, JF424881.1, JF424882.1, JF424883.1, JF424884.1, JF424885.1, JF424886.1, JF424887.1, JF424888.1, JF424889.1, JF424890.1, JF424891.1, JF424892.1, JF424893.1, JF424894.1, JF424895.1, JF424896.1, JF424897.1, JF424898.1, JF424899.1, JF424900.1, JF424901.1, JF424902.1, JF424903.1, JF424904.1, JF424905.1, JF424906.1, JF424907.1, JF424908.1, JF424909.1, JF424910.1, JF424911.1, JF424912.1, JF424913.1, JF424914.1, JF424915.1, JF424916.1, JF424917.1, JF424918.1, JF424919.1, JF424920.1, JF424921.1, JF424922.1, JF424923.1, JF424924.1, JF424925.1, JF424926.1, JF424927.<h2 style=";text-align:left;direction:ltr">1, JF424928.1, JF424929.1, JF424930.1, JF424931.1, JF424932.1, JF424933.1, JF424934.1, JF424935.1, JF424936.1, JF424937.1, JF424938.1, JF424939.1, JF424940.1, JF424941.1, JF424942.1, JF424943.1, JF424944.1, JF424945.1, JF424946.1, JF424947.1, JF424948.1, JF424949.1, JF424950.1, JF424951.1, JF424952.1, JF424953.1, JF424954.1, JF424955.1, JF424956.1, JF424957.1, JF424958.1, JF424959.1, JF424960.1, JF424961.1, JF424962.1, JF425488.1, JF425489.1, JF425490.1, JF425491.1, JF425492.1, JF425493.1, JF425494.1, JF425495.1, JF425496.1, JF425497.1, JF425498.1, JF425499.1, JF425500.1, JF425501.1, JF425502.1, JF425503.1, JF425504.1, JF425551.1, JF425552.1, JF425553.1, JF425554.1, JF425555.1, JF425556.1, JQ237146.1, JQ823124.1, JX273163.1, KJ659286.1, KJ659287.1, KJ659288.1, KJ659289.1, KM225765.1, LC164349.1, LC164350.1, LC164351.1, LC164352.1, LC164353.1, LC164354.1, MF662180.1, MF662181.1, MF662182.1, MF662183.1, MF662184.1, MF662185.1, MF662186.1, MF662187.1, MF662188.1, MF662189.1, MF662190.1, MF662191.1, MF662192.1, MF662193.1, MF662194.1, MF662195.1, MF662196.1, MF662197.1, MF662198.1, MF662199.1, MF662200.1, MF662201.1, MF662202.1, MF662203.1, MF662204.1.
[0141] KIPyV:EF520287.1, EF520288.1, EF520289.1, EU358766.1, EU358767.1, KC571691.1, KM085447.1, KU746835.1
[0142] <h2 style=";text-align:left;direction:ltr">WUPyV: EF444549.1, EF444550.1, EF444551.1, EF444552.1, EF444553.1, EF444554.1, EU296475.1, EU358768.1, EU358769.1, EU711054.1, EU711055.1, EU711056.1, EU711057.1, EU711058.1, FJ794068.1, FJ890981.1, FJ890982.1, GQ926975.1, GQ926976.1, GQ926977.1, GQ926978.1, GQ926979.1, GQ926980.1, GU296361.1, GU296362.1, GU296363.1, GU296364.1, GU296365.1, GU296366.1, GU296367.1, GU296368.1, GU296369.1, GU296370.1, GU296371.1, GU296372.1, GU296373.1, GU296374.1, GU296375.1, GU296376.1, GU296377.1, GU296378.1, GU296379.1, GU296380.1, GU296381.1, GU296382.1, GU296383.1, GU296384.1, GU296385.1, GU296386.1, GU296387.1, GU296388.1, GU296389.1, GU296390.1, GU296391.1, GU296392.1, GU296393.1, GU296394.1, GU296395.1, GU296396.1, GU296397.1, GU296398.1, GU296399.1, GU296400.1, GU296401.1, GU296402.1, GU296403.1, GU296404.1, GU296405.1, GU296406.1, GU296407.1, GU296408.1, HQ218321.1, KC571693.1, KC571694.1, KC571695.1, KC571696.1, KC571697.1, KC571698.1, KC571699.1, KJ643309.1, KJ725028.1, KM265136.1, KU049032.1, KU672381.1, KX650181.1, KX650182.1, KX650184.1, KX650185.1, KX650186.1, KX650187.1, KX650188.1, KX650189.1, KX650190.1, KX650191.1, KX650192.1, KX650193.1.
[0143] MCPyV:EU375803.1, EU375804.1, FJ173815.1, FJ464337.1, HM011538.1, HM011539.1, HM011540.1, HM011541.1, HM011542.1, HM011543.1, HM011544.1, HM011545.1, HM011546.1, HM011547.1, HM011548.1, HM011549.1, HM011550.1, HM011551.1, HM011552.1, HM011553.1, HM011554.1, HM011555.1, HM011556.1, HM011557.1, HM355825.1, JF812999.1, JF813000.1, JF813001.1, JF813002.1, JF813003.1, JN383838.1, JN383839.1, JN383840.1, JN383841.1, JQ479315.1, JQ479316.1, JQ479317.1, JQ479318.1, JQ479319.1, JQ479320.1, JX045708.1, JX045709.1, KC202810.1, KC571692.1, KF266963.1, KF266964.1, KF266965.1, KX781279.1, KX827417.1, NC_010277.2
[0144] HPyV6:HM011558.1, HM011559.1, HM011560.1, HM011561.1, HM011562.1, HM011563.1, KM387421.1, KM655817.1, KR090570.1, KU596573.1, KX379630.1, KX379631.1, KX771234.1
[0145] HPyV7:HM011564.1, HM011565.1, HM011566.1, HM011567.1, HM011568.1, HM011569.1, KJ733012.1, KJ733013.1, KX771235.1
[0146] TSPyV:AB873001.1, JQ723730.1, KF444091.1, KF444092.1, KF444093.1, KF444094.1, KF444095.1, KF444096.1, KF444097.1, KF444098.1, KF444099.1, KF444100.1, KF444101.1, KM007161.1, KM655816.1, KU221329.1, KX249740.1, KX249741.1, KX249742.1, KX249743.1
[0147] HPyV9:HQ696595.1 , KC831440.1
[0148] MWPyV:JQ898291.1, JQ898292.1, KC549586.1, KC549587.1, KC549588.1, KC549589.1, KC549590.1, KC549591.1, KC549592.1, KC549593.1, KC549594.1, KC571700.1, KC571701.1, KC571702.1, KC571703.1, KC571704.1, KC571705.1, KC690147.1, KR338953.1
[0149] STLPyV:JX463183.1, JX463184.1, KF525270.1, KF530304.1, KF651951.1, KM893862.1, KR090571.1, NC_020106.1
[0150] HPyV12:JX308829.1, NC_020890.1
[0151] NJPyV:KF954417.1, NC_024118.1
[0152] (Splice site conservation and phylogenetic tree) The entire gene sequence of TAg, including intron sequences, was aligned against 13 different polyomavirus reference sequences and all unique BK polyomavirus isolates using clustalW (package "msa" in R). Phylogenetic trees were constructed using the UPGMA method (packages "phangorn" and "ggtree" in R). Sequence logos were constructed for the acceptor and donor splice sites to show nucleotide-specific conservation between subtypes (package "msa" in R).
[0153] (Designed by AON) Antisense oligonucleotides targeting splice sites in TAg We designed ribonucleic acids (AONs). The ribonucleic acids in these AONs contain 2'-OMe modifications. The AONs are 20 nucleotides long and contain a phosphorothioate backbone ( * ). For in vitro studies, the AONs contain a 5'-FAM label. The secondary structures and binding energies of the AONs were predicted using the RNA structure. All AON sequences are shown below:
[0154] [Table 4]
[0155] (cell culture) Immortalized proximal tubule kidney epithelial HK2 cells (ATCC® CRL-2190 TM) was obtained from ATCC and maintained at 37°C, 5% CO2 in a 1:1 mixture of Dulbecco's modified Eagle's medium-F12 containing 15 mM Hepes, 2.5 mM L-glutamine (Lonza) and supplemented with triiodothyronine, epidermal growth factor (EGF), insulin-transferrin-selenium-ethanolamine (ITS-X), hydrocortisone and 100 U / mL penicillin-streptomycin. BK polyomavirus (ATCC® VR-837 TM ) were obtained from ATCC and diluted in complete HK2 medium to reduce the infectious load. For treatment experiments, 32,000 cells / cm were plated in 6- or 12-well plates (Corning). 2 The cells were seeded at a density of 100 μg / ml and grown overnight. AON treatment was performed by incubating with 50 nM AON concentration with Fisher (Fisher) for 5 hours, followed by washing off the lipofectamine. 24 hours after washing the cells were infected with BK polyomavirus by incubating the cells with BK polyomavirus-containing medium for 2 hours, followed by washing off the virus. Supernatants were collected after washing and at 3, 5, and 7 days post-infection, and viral particle production was measured using PCR. Viral load samples were collected pre-infection to measure the amount of infection. RNA and protein were collected on day 7 to measure TAg and VP1 expression.
[0156] (Measurement of viral load) To measure viral load in culture supernatants, 200 μL was collected from all wells at all time points. Unpackaged DNA was degraded for 15 min at room temperature by adding Pierce Universal Nuclease to all samples, and then inactivated with 5 mM EDTA. Viral DNA was isolated from the supernatants using a DNA mini kit (Qiagen) and viral load was measured using Taqman PCR as described below (Wunderink, HF, et. al., J. Clin. Virol., 2017). A low concentration of herpesvirus was added to the lysis buffer to monitor the quality of DNA extraction and possible PCR inhibition. DNA was eluted in a final volume of 100 μL elution buffer, of which 10 μL was used as input for real-time quantitative PCR (qPCR). A 90 bp fragment within the BKPyV VP1 gene was amplified using primers 440BKVs 5'-GAAAAGGAGAGTGTCCAGGG-3' and 441BKVas 5'-GAACTTCTACTCCTCCTTTTATTAGT-3' and Taqman probe 576BKV-TQ-FAM FAM 5'-CCAAAAAGCCAAAGGAACCC-3'-BHQ1. BKPyV qPCR and phocine herpesvirus PCR were performed in duplicate to monitor DNA quality and possible PCR inhibition. Additionally, BKPyV qPCR was validated to detect BKPyV genotypes I-IV.
[0157] Quantitative PCR reactions were performed in a total volume of 50 μL containing 25 μL of HotStarTaq Master Mix (QIAGEN, Hilden, Germany), 0.5 μmol / L of each primer, 0.35 μmol / L BKPyV probe, and 3.5 mmol / L MgCl2. Reactions were performed using a CFX96 real-time detection system (Bio-Rad, Hercules, CA, USA) with the following cycle conditions: 95°C for 15 min, followed by 45 cycles of amplification (95°C for 30 s; 55°C for 30 s; 72°C for 30 s). For quantification, a quantified BKPyV-positive urine sample was used as a standard. The analytical sensitivity of the BKPyV qPCR was approximately 10 copies / mL. On each plate, three negative controls were included; these controls tested negative in all PCR assays. PCR results with a cycle threshold of ≥40 were considered negative.
[0158] (Antibodies and Western Blot) Protein concentration was measured using the BCA method. Samples were run on 4-15% TGX gels and transferred to nitrocellulose or PVDF membranes. The antibodies used were rabbit polyclonal anti-actin-HRP (loading control), rabbit polyclonal anti-SV40 VP1 (ab53977, Abcam), mouse monoclonal anti-SV40 T antigen [PAb416] (ab16879, Abcam) and mouse monoclonal anti-SV40 T antigen (PAb108, Thermo Fisher). Primary antibodies were incubated overnight at 4°C for TAg and VP1, and 30 min at RT for actin. Secondary antibodies used for TAg and VP1 were goat polyclonal anti-mouse-HRP (P044701-2, Agilent) and goat polyclonal anti-rabbit-HRP (P044801-2, Agilent), respectively. The membranes were stained with SuperSignal TMAfter incubation with West Femto Maximum Sensitivity Substrate (Thermo Fisher), protein bands were visualized using a ChemiDoc MP Imaging System (Bio Rad).
[0159] (Real-time qPCR) HK2 cells infected with BK were lysed with Trizol and RNA was isolated using the RNeasy kit (Qiagen). During the isolation, DNase I (Qiagen) treatment was performed to remove excess DNA, and cDNA was synthesized using Promega reverse transcriptase, DTT, dNTPs and random primers. CFX384 Touch TM SYBR Real-Time PCR Detection System (BioRad) TM Real-time PCR was performed using Select Master Mix (Thermo Fisher) and the following primers:
[0160] [Table 5]
[0161] (result) (Design of antisense oligonucleotides targeting BK) Effective antisense oligonucleotides (AONs) targeting the BKPyV large T antigen (TAg) must be specific to BKPyV, in the sense that they are not specific to the host RNA species, but preferably as universal as possible to other different BKPyV isolates and different polyomaviruses in general. Compared to dsRNA / ssRNA viruses, dsDNA viruses (in this case, polyomaviruses) are characterized by less genetic drift. Nevertheless, there remains a large number of BKPyV genotypes and subgenotypes resulting in a large number of BKPyV serotypes (see phylogenetic tree in Figure 2). As TAg contains two exons, we first identified the genomic sequence of exon-intron junctions to identify AON candidates (see Figure 2). To achieve this, we extracted the available unique BKPyV TAg genomic sequences (n=245 accession numbers provided in Materials and Methods) from the NCBI database and aligned them using ClustalW. Regions that showed a high level of sequence similarity (or conservation) were targeted. These studies showed a high degree of conservation in exon 1 and adjacent intronic sequences (see Figure 2). Exon 2 also showed a high level of sequence conservation. The adjacent intronic sequences were T nucleotide rich while at the same time less conserved within 4 nucleotides of the exon boundaries. AONs were targeted against exon 1 of BKPyV TAg and bridging portions of the intronic sequences in exon 1. For exon 2, AONs were targeted against the intronic region of exon 2 and 4-6 nucleotides in the adjacent exon 2 sequences.
[0162] As shown in Figure 3, we decided to design five AONs targeting BKPyV TAg, three of which target the exon 1-intron portion (designated AON#1, #2, and #3), and two AONs target the exon 2-intron portion (designated AON#4 and #5). The AONs gradually shift from mainly exonic sequences to including important intron binding sequences in the case of exon 1-targeting AONs (AON1-3). See Materials and Methods and Figure 3 for the exact sequences and modifications of backbone and sugar moieties. This design allowed us to specifically target the TAg of BKPyV while being universal for different BKPyV genotypes in kidney transplant patients.
[0163] AON-mediated reduction of BKPyV TAg RNA We used lipofectamine-based AON delivery and found that AON uptake was significantly improved within 5 hours after transfection. Furthermore, we titrated the AON dose until it reached a maximum at approximately 50 nM based on the FAM labeling intensity of the cells. Twenty-four hours (24 h) after AON administration, HK2 cells were infected with BKV for 2 hours, and then the cells were washed and cultured for 3, 5, and 7 days. At these time points, RNA was harvested from the cells and qRT-PCR was performed to determine which AONs could affect the expression level of TAg. HK2 cells not transfected with AONs (untreated) showed similar TAg expression levels to those treated with scrambled AONs (Scr) (data not shown).
[0164] A significant proportion of AONs designed to modulate the expression level or splicing of a given target RNA prove to be effective. Our studies with AONs #2, #3 or #4 repeatedly and significantly reduced TAg RNA levels, generally showing a 5- to 10-fold attenuation of the RNA levels of this viral DNA driver (see FIG. 4, left panel). BKPyV-infected cultures treated with AONs #2, #3, #4 or #5 repeatedly showed reduced TAg RNA expression levels. This validates the sites targeted by these AONs as preferred target sites for the reduction of BK virus production by reducing the production of TAg. Notably, this reduction is observed at high MOI settings, i.e., in the range of 100.
[0165] AON-mediated reduction of VP1 RNA and protein In cells latently infected with polyomaviruses (e.g., renal proximal tubule cells infected with BKV), low levels of TAg RNA and protein expression are maintained. In individuals with compromised immune systems, whether natural or induced by immunosuppressive regimens, induction of viral replication and TAg expression is observed (Hasegawa, M. et.al., Transplantation Proceedings, 2014; Nickeleit, V. et.al., JASN, 2018). Increased TAg levels, together with interaction with accessory transcription factors on the non-coding / promoter regions of the BKV genome, drive both BK genome replication and (late region) major capsid protein expression. In summary, TAg-mediated activation of viral DNA replication and encapsulation by capsid proteins generates infectious viral particles that can be detected both in urine (viruria) and serum (viremia) (Helle, F. et. al., Viruses, 2017).
[0166] To test whether AONs are effective in reducing BKV production, we measured the expression profile of proteins activated by TAg, including VP1. VP1 is the main structural component of the icosahedral viral capsid. This shell has 72 pentamers bound to VP2 or VP3 with a 5:1 stoichiometry. Therefore, we performed qRT-PCR for VP1, which revealed that the expression level of VP1 per copy of GAPDH was much higher than that of TAg (data not shown). This is consistent with the fact that TAg induces the expression of VP1 mRNA together with other transcription factors. Moreover, in all studies, our AONs #2, #3, #4 and #5 significantly reduced the expression level of VP1 RNA as well as VP1 protein (see Figure 5, right panel).
[0167] We also tested whether the combination therapy of AON#2 and #4 could more effectively reduce the RNA levels of TAg and VP1. This combination was selected based on the fact that the above-mentioned Western blot for VP1 in AON-treated cells (Figure 5) suggested that VP1 protein was most strongly reduced by these two AONs. Based on the mRNA expression levels of TAg and VP1, this combination treatment did not provide any evidence to suggest that they were more effective (Figure 4).
[0168] This observed reduction in VP1 indicates that the TAg splicing-targeting AON is effective. By reducing TAg RNA (and potentially protein expression), the expression levels of BKPyV late region genes and corresponding proteins are reduced. In addition, VP1 also plays a central mediating role in the infectivity of newly formed virus particles by binding to the cell surface of nearby and / or distant cells at sialic acids on glycans, along with the role of VP1 in encapsulation of viral DNA (Helle, F. et. al., Viruses, 2017). Thus, the infectivity of BKPyV may be impaired when VP1 protein is reduced (or absent).
[0169] (TAg splicing-targeting AON reduces BK virus titers) Concurrently with screening for TAg and VP1 RNA and protein levels (day 7) in HK2 cells pretreated with our TAg splicing-targeting AONs, we assessed the viral load in culture supernatants 3, 5, and 7 days after BKPyV infection. Because a reduction in TAg expression could potentially affect both viral genome replication and VP1 protein production, we determined whether a reduction in VP1 affected the production of encapsulated viral DNA. We measured viral particles in culture supernatants by quantifying encapsulated DNA. To distinguish between encapsulated and non-encapsulated DNA, we applied (endo)nuclease treatment to digest non-encapsulated DNA. As shown in Figure 6, these studies revealed that AON#1 reduced viral DNA levels at day 3 but not at day 7, and this level was normalized to and similar to the viral DNA levels in cells treated with scrambled AONs (Figure 6). AONs #2, #3 and #4 were characterized by reduced viral titers at both time intervals, and AONs #2, #3 and #4 in particular attenuated encapsulated viral DNA by up to 6-fold (Figure 6). The combination of AONs #2 and #4 mentioned above only slightly reduced viral loads on days 3 and 7 (Figure 6).
[0170] Thus, AON-mediated reduction in TAg and VP1 RNA and protein reduces virus production.
[0171] (Alkyl modification at the 2' position of the ribose sugar) Alterations to the 2' position of the ribose sugar on the AON affect the ability to reduce TAg and VP1 RNA and protein levels, as well as BKV DNA production (Figure 7). The data presented above are based on 2'-O methyl (2'-OMe) modification of the ribose sugar on each nucleotide within the antisense oligonucleotide. RNA and protein were harvested from HK2 cells pretreated with both 2'-OMe or 2'-methoxy (2'-MOE) nucleotides (see Figure 7).
[0172] (TAg splicing targeting AONs against other polyomaviruses) Besides BKV, we have also developed AONs that similarly target TAg against JC virus (JCV). JCV has 75% sequence similarity to BKV (the level of conservation observed at exon 1-intron junction), whereas the sequence similarity at the intron-exon 2 junction is essentially 100% (Figure 8). Thus, AONs targeting exon 2 of BKV can also reduce JCV abundance. JCV can also infect renal cells, such as proximal tubule cells, which are believed to be secondary infection sites, after primary infection via the tonsils and / or gastrointestinal tract. Thus, TAg splicing targeting AONs, especially those targeting the intron-exon 2 splice site, can simultaneously suppress the production of BKV and JCV. Furthermore, we have generated novel AONs that target the unique JCV exon 1-intron sequence.
[0173] Given that the genomic sequences at the exon 1-intron and intron-exon 2 junctions of TAg have been determined for all known polyomaviruses, it is possible to design AONs that affect the splicing of TAg in any of these polyomaviruses (Figure 9). Examples of AONs suitable for other polyomaviruses are shown in FIG.
[0174] [Example 2] (material and method) Phylogenetic conservation of BKV subtypes
[0175] The whole genome sequences of BK polyomavirus isolates were downloaded from the publicly available NCBI database (before 07-09-2018). From these records, only isolates with reported whole genomes were used for the analysis. Isolates "MM" and "FNL-9" were removed because they had large deletions in introns or duplications partially matching the acceptor splice site, respectively. By removing the identical sequences, 248 unique genomic sequences were obtained, the accession numbers of which are provided below: AB211369, AB211370, AB211371, AB211372, AB211373, AB211374, AB211375, AB211376, AB211377, AB211378, AB211379, AB211381, AB211382, AB211383, AB211384, AB211385, AB211386, AB211387, AB211388, AB211389, AB211390, AB211391, AB213487, AB217917, AB217918, AB217919, AB217920, AB217921, AB260028, AB260029, AB260030, AB260031, AB260032, AB260033, AB263912, AB263913, AB263914, AB263915, AB263916, AB263917, AB263918, AB263919, AB263920, AB263921, AB263922, AB263923, AB263924, AB263925, AB263926, AB263927, AB263928, AB263929, AB263930, AB263931, AB263932, AB263934, AB263935, AB263936, AB263938, AB269825, AB269826, AB269827, AB269828, AB269829, AB269830, AB269831, AB269832, AB269834, AB269836, AB269837, AB269838, AB269840, AB269841, AB269842, AB269843, AB269844,<h2 style=";text-align:left;direction:ltr">AB269845, AB269846, AB269847, AB269848, AB269849, AB269850, AB269851, AB269852, AB269853, AB269854, AB269855, AB269856, AB269857, AB269858, AB269859, AB269860, AB269861, AB269862, AB269863, AB269864, AB269865, AB269866, AB269867, AB269868, AB269869, AB298941, AB298942, AB298945, AB298946, AB298947, AB301086, AB301087, AB301089, AB301090, AB301091, AB301092, AB301093, AB301094, AB301095, AB301096, AB301097, AB301099, AB301100, AB301101, AB365130, AB365132, AB365133, AB365134, AB365136, AB365137, AB365138, AB365139, AB365140, AB365141, AB365142, AB365144, AB365145, AB365146, AB365148, AB365149, AB365150, AB365151, AB365153, AB365154, AB365156, AB365157, AB365158, AB365159, AB365160, AB365162, AB365164, AB365165, AB365166, AB365167, AB365168, AB365170, AB365173, AB365174, AB365175, AB365176, AB365178, AB369087, AB369088, AB369089, AB369090, AB369092, AB369093, AB369094, AB369095, AB369096, AB369097, AB369098, AB369099, AB369101, AB464953, AB464954, AB464956, AB464957, AB464958, AB464960,AB464961, AB464962, AB485695, AB485696, AB485697, AB485698, AB485699, AB485700, AB485701, AB485703, AB485704, AB485707, AB485709, AB485710, AB485711, AB485712, AY628224, AY628225, AY628226, AY628227, AY628228, AY628229, AY628230, AY628231, AY628232, AY628233, AY628234, AY628235, AY628236, AY628237, AY628238, DQ305492, EF376992, FR720308, FR720309, FR720310, FR720311, FR720312, FR720313, FR720315, FR720317, FR720318, FR720320, FR720321, JF894228, JN192431, JN192432, JN192433, JN192435, JN192437, JN192438, JN192439, JN192440, JQ713822, KF055891, KF055892, KF055893, KP412983, KP984526, KY114802, KY114803, KY132094, KY487998, LC029413, LC309239, LC309240, LT960370, M23122, MF358970, MF627830, MF627831, V01108. ,
[0176] (Splice site conservation and phylogenetic tree) The entire gene sequence of TAg, including intron sequences, was aligned using Prank (v.140603). Manual adjustments were made to the aligned sequences to correct for imperfections in aligning deletions. A phylogenetic tree was constructed using the neighbor-joining method (MEGA version 10.0.5) with bootstrapping (1000 iterations) and the Kimura2-parameter model. The tree was further visualized in R ("ggtree"), and sequence logos were constructed ("ggseqlogo") for the acceptor and donor splice sites to show nucleotide-specific conservation among subtypes. The subtypes of sequences were determined using the reference sequence reported by Zhong et al. (Zhong, J Gen Virol, 2009).
[0177] (Oligonucleotide design) Antisense oligonucleotides were designed as described in Example 1. For in vivo studies, 5'6-FAM non-labeled 2'-MOE AON (HYB_01) was used.
[0178] (animal) Male C57BL6 / J mice aged 6-10 weeks were injected intravenously with 40 mg / kg 5'6-FAM-unlabeled 2'-MOE AONs or saline (volume corrected for body weight +- 100 uL). 24 days after administration of AONs or saline, animals were sacrificed by venous exsanguination under isoflurane anesthesia. Organs were removed, fixed in formalin, and embedded in paraffin.
[0179] (cell culture) Human renal proximal tubule epithelial cells (HK2, ATCC®) were cultured in Dulbecco's modified Eagle's medium supplemented with 3,3',5-triiodo-L-thyronine sodium salt (Sigma-Aldrich), insulin-transferrin-selenium-ethanolamine (ITS-X; Sigma-Aldrich), human epidermal growth factor (EGF; Sigma-Aldrich), hydrocortisone (Sigma-Aldrich), and 100 U / mL penicillin-streptomycin (Gibco) in a nutrient mixture. Human renal proximal tubule epithelial cells (PTEC, Sciencell Research Laboratories) were cultured in complete REGM. TM Primary human astrocytes (Sciencell Research Laboratories) were maintained in complete Astrocyte Medium (Sciencell Research Laboratories). iPSC-derived astrocytes and oligodendrocytes were maintained in complete BrainPhys TM Cells were maintained in Neuronal Medium (Stemcell Technologies). All cells were cultured at 37°C and 5% CO2.
[0180] Treatment of cells with AONs and viral infection Cells were seeded at the required cell density and cultured overnight. Cellular uptake of AONs was performed by culturing cells in the presence of 50 nM AONs for 4 h with Lipofectamine 2000 (human astrocytes and iPSc astrocytes / oligodendrocytes, Invitrogen) or for 5 h with Lipofectamine 3000 (HK2 and PTEC, Invitrogen), after which the cells were washed with regular culture medium. BKV infection of HK2 epithelial cells or human kidney epithelial cells was performed as described in Example 1. Astrocytes / oligodendrocytes were infected with JC polyomavirus (strain MAD-4, ATCC® VR-1583) and cultured overnight. TMJCV infection of the cells was performed by culturing them overnight in the presence of 5% PFA. The cells were washed extensively after infection to remove excess viral particles. The culture medium was partially refreshed and supernatant samples were taken at specific time points after infection to examine viral particle production. Reinfection of the cells was performed by harvesting the supernatant of wells containing infected cells after treatment. This supernatant was then diluted two-fold and transferred to new wells containing uninfected and untreated cells for 2 h, after which the cells were washed extensively. After 7 days, the infected cells were washed with 4% PFA.
[0181] (Measurement of viral load) Viral load in culture supernatants was performed as described in Example 1, with the following exceptions: 1) 100 μL samples were collected from all wells at all time points, and 2) unpackaged DNA was degraded using the TURBO DNA-free kit (Invitrogen) prior to isolation.
[0182] (Real-time qPCR) RNA isolation, cDNA synthesis and real-time qPCR were performed as described in Example 1. However, after RNA isolation, residual DNA was purified using the TURBO DNA-free kit. (Invitrogen). To amplify the T antigen splice variant, the Phusion® High-Fidelity PCR Kit was used with HF buffer and the following primers: forward ATGGAGCTCATGGACCTTTTAGG, reverse TGCAACTCTTGACTATGGGGG. qPCR detection of JC virus RNA was performed with the following primers:
[0183] [Table 6]
[0184] (antibody) The following primary antibodies were used: rabbit anti-SV40 VP1 (ab53977), mouse anti-SV40 T antigen (PAb416), mouse anti-SV40 T antigen (PAb108), rabbit anti-GAPDH (D16H11), biotinylated Lotus Lectin (LTL,B-1325). Rabbit anti-phosphorothioate antibody was kindly provided by Jonathan Watts (UMASS Medical School, MA, USA). The following secondary antibodies were used: goat anti-rabbit Alexa488 (A11008), goat anti-rabbit Alexa568 (A11011), goat anti-rabbit HRP (P044801-2), and streptavidin Alexa532 (S11224).
[0185] (Protein quantification) Protein lysates were generated by lysing cells in lysis buffer (pH 7.5) containing 50 mM Tris-HCl, 150 mM NaCl, 1% SDS, 0.5% deoxycholate, 0.5% Triton X-100 and protease inhibitors. Pierce TM BCA Protein Assay Kit(Thermo Fisher Protein concentrations of samples were measured using a ELISA kit (ProteinSimple, Inc.). Quantitation of protein expression was performed using a Wes Simple Western automated immunoassay system equipped with a 12-230 kDa separation matrix and an anti-rabbit detection module (ProteinSimple).
[0186] (immunohistochemistry) For reinfection experiments, cells were fixed with 4% PFA and permeabilized in 0.3% Triton-X / 3% BSA (Merck, Zwijndrecht, the Netherlands) / 1% NGS (Dako, Amstelveen, the Netherlands) / 1% FCS in PBS for 1 h at RT. Primary antibodies were incubated overnight in 3% BSA / 1% NGS / 1% FCS in PBS at 4°C, after which cells were washed extensively and incubated with secondary antibodies for 1 h at RT. Image collection and quantification of reinfected cells were performed using (TAg+ ) was performed using the ImageXpress Micro High-Content Imaging System and MetaXpress software, using a custom module to identify and count nuclei. Further processing of the in vivo images (color deconvolution and thresholding) was performed using ImageJ.
[0187] Mouse organs were embedded in paraffin, sectioned, slides dewaxed, rehydrated, and endogenous peroxidase was quenched in 3% H2O2 in methanol for 10 min at room temperature. Antigen retrieval was performed with proteinase K (Agilent, Amstelveen, the Netherlands) for 10 min at room temperature, followed by a blocking step with Background Buster (Innovex, Gujarat, India). Between steps, slides were washed in TBS / Tween. Primary antibody incubations (anti-phosphorothioate or LTL) were performed in 2% BSA / 5% NGS in TBS / Tween at 4°C. Secondary antibody incubations were performed for 90 min at room temperature. Nuclei were stained with Hoechst33258 (Molecular Probes, Leiden, the Netherlands) and slides were mounted with Prolong Gold (Invitrogen). Image acquisition was performed using Pannoramic MIDI II (3DHISTECH, Budapest, Hungary).
[0188] (Next Generation Sequencing) RNA-seq was performed on RNA samples derived from infected HK2 cells treated with AONs using Illumina sequencing technology. Briefly, sample quality was measured using a Fragment Analyzer and the samples were processed using the NEBNext Ultra II Directional RNA Library Prep Kit for Illumina. The sample preparation was performed according to the protocol of the "NEBNext Ultra II Directional RNA Library Prep Kit for Illumina" (NEB #E7760S / L). Briefly, rRNA was depleted from total RNA using the rRNA Depletion Kit (NEB #E6310). Fragmentation of the rRNA-reduced RNA was followed by cDNA synthesis, which was used for ligation with sequencing adapters and PCR amplification of the resulting products. The quality and yield after sample preparation were measured using a Fragment Analyzer. The size of the resulting products was consistent with the expected size distribution (broad peak of 300-500 bp). Clustering and DNA sequencing using NovaSeq6000 were performed according to the manufacturer's protocol. A DNA concentration of 1.1 nM was used. NovaSeq Control Software NCS Image analysis, base calling and quality checking were performed using the Illumina data analysis pipeline RTA3.3.5 and Bcl2fastq v2.20.
[0189] The human reference Homo_sapiens.GRCh38.dna.primary_assembly was combined with the viral reference LC029411.1. The combined genome was used to align the reads for each sample. The reads were mapped to the reference sequence using a short read aligner based on the Burrows-Wheeler Transform (Tophat v2.0.14) with default settings. The frequency with which reads mapped onto transcripts was measured using HTSeq v0.6.1p1 based on the mapped position in the alignment file.
[0190] (Identifying splicing events using Eventpointer) To identify alternative splicing events in the NGS data, "Eventpointer" was applied to the reads mapped to the viral reference genome. The resulting splicing events were quantified using Kallisto to obtain percent splicing (PSI) values for each event. For statistical testing, scrambled AONs were used as a control condition.
[0191] (Pacific Biosciences long-read sequencing) First, RNA integrity was assessed in a bioanalyzer. cDNA synthesis was performed using the SMARTer cDNA synthesis kit (Takara), and specific large T products were amplified using Kapa HiFi HotStart Ready Mix (Roche). The cDNA products were size-selected and then amplified using the SMRTbell Barcoded Amplicons were barcoded for each sample using the Adapter Complete Prep Kit (PacBio), then equimolar pooled and purified using PacBio Sequencing was performed in Sequel 1M v3 LR SMRT cells.
[0192] Transcript identification, polishing and annotation were performed using the Iso-Seq3 bioinformatics pipeline (https: / / github.com / PacificBiosciences / IsoSeq3) published by Pacific Biosciences. First, reads were divided into full-length and non-full-length based on the presence of sample-specific barcodes. To find transcript clusters, an isoform-level clustering algorithm (ICE) performed pairwise alignment and iterative assignment of full-length reads to cluster them based on likelihood. After ICE, partial reads were added to isoform clusters to increase coverage for the final consensus using the Arrow algorithm. The output from the above bioinformatics pipeline is a set of full-length transcript sequences that can be mapped to reference sequences to build annotation files in GFF format. Based on the predicted consensus accuracy of the Arrow algorithm, sequences of transcripts with a predicted accuracy of >99% (excluding QV from the first 100bp and last 30bp due to occasional insufficient coverage for accurate estimation of accuracy) were considered as HQ transcripts and used for further analysis. Sequences of HQ transcripts were mapped back to the reference sequences and filtered for >99% alignment coverage and >85% alignment identity. Redundant transcripts were collapsed to create the final dataset used in this study.
[0193] (result) (Development of novel BKV-targeting AONs) As shown in Figures 10 and 11, in parallel with our previous AONs, we decided to design nine new AONs targeting BKV TAg. Six of the nine target the exon 1-intron portion (named HYB_06, _07, _08, _09, _10 and _11), and two new AONs target the exon 2-intron portion (named HYB_12 and _13). Along with these nine new TAg exon-intron junction targeting AONs, we also tested two AONs previously reported by Santaris Pharma (WO2012 / 143427A1), which have a different composition from our AONs but are complementary to a part of the exon 1-intron junction (SAN_74) or simply a part of exon 2 (SAN_73). Additionally, we have designed and tested an AON, namely HYB_14, that binds exclusively to the coding region of exon 1. These AONs gradually shift from predominantly exonic sequences to including important intron binding sequences in the case of exon 1-targeting AONs (collectively referred to here) (HYB_01, _02, _03, _06, _07, _08, _09, _10, _11) and exon 2-targeting AONs (HYB_04, _05, _12 and _13).
[0194] AON-mediated reduction of BKV TAg RNA BKV-targeted AONs showed a range of efficacy in reducing TAg mRNA levels. As shown in Figures 12 and 19, among the 14 AONs designed to target exon-intron junctions of TAg, HYB_01, HYB_03, and HYB_11 induced the greatest reduction in TAg mRNA expression, generally in the range of 8-fold or greater at the RNA level of this viral DNA driver, 7 days after infection.
[0195] Furthermore, our data also suggest that AONs targeting exon 1-intron junction are more effective in reducing TAg mRNA levels than AONs targeting exon 2-intron junction (HYB_04, HYB_05, HYB_12 and HYB_13). This trend is bioinformatically shown in Figures 18 and 25, where only HYB_05 clusters with AONs targeting exon 1-intron junction. Similarly, SAN_73 and SAN_74 were found to be almost ineffective in reducing TAg mRNA expression levels. Of note, these reductions in TAg mRNA are observed at high MOI settings, i.e., in the range of 100.
[0196] Along with HK2 cells, we also tested our BKV-targeting AONs in primary proximal tubule epithelial cells (hPTECs). Based on the significant and consistent reduction in TAg mRNA expression levels observed in HK2 cells with HYB_01, HYB_03 and HYB_11, we decided to proceed and called these three our "lead compounds". As shown in Figure 28, HYB_01, HYB_03 and HYB_11 all dramatically reduced the expression of TAg mRNA in hPTECs (n=3 biological repeats), while HYB_14 proved to be ineffective in reducing TAg mRNA levels in hPTECs.
[0197] Interestingly, most of our studies include pretreatment with AONs before infection with BKV. A preliminary study in which we first infected HK2 cells with BKV and then treated them with AONs (i.e., HYB_01) revealed that our BKV-targeted AONs could efficiently suppress BKV TAg expression in BKV-bearing cells 7 days after infection (FIG. 26, left panel), and that multiple administrations after infection could potentially further suppress the expression level of TAg mRNA (FIG. 26, right panel).
[0198] AON-mediated reduction of VP1 RNA and protein Interestingly, the expression level of VP1 mRNA was reduced by most of the BKV-targeted AONs, except for HYB_04, HYB_12, HYB_13 and HYB_14 (Figures 13 and 20). Similar to our results obtained for TAg mRNA, HYB_01, HYB_03 and HYB_11 significantly reduced VP1 RNA expression, especially in HK2 cells (Figure 13). Moreover, regardless of whether HYB_01 was administered before or after infection of HK2 cells with BK virus, the AON efficiently reduced VP1 mRNA levels (Figure 26, left and right panels). Importantly, the observed reduction in VP1 mRNA led to a dramatic attenuation of VP1 protein levels in HK2 cells (Figures 14-15 and 21-22). Consistent with our observations on TAg mRNA levels, SAN_73 and SAN_74 did not significantly affect VP1 mRNA and protein expression levels.
[0199] As shown in Figures 29-31, HYB_01, HYB_03 and HYB_11 all dramatically reduced VP1 mRNA and protein expression in hPTECs (n=3 biological replicates). Furthermore, HYB_14 did not affect VP1 mRNA and protein levels. Furthermore, we obtained preliminary evidence that our AONs also effectively reduced VP3 protein levels (Figures 30 and 32).
[0200] (Infection and reinfection of human proximal tubular epithelial cells) We next evaluated whether the broad combination of our BKV-targeted AONs could affect the degree of infection and reinfection by BKV in HK2 cells.To achieve this, we first treated HK2 cells with BKV-targeted AONs and infected them with BKV.After 7 days, we collected the viral particle-containing supernatant and used it to infect a new batch of untreated HK2 cells.After 7 days, we performed fluorescent immunostaining on the cells infected with TAg and scored them as percent positive (by counterstaining nuclei with Hoechst).As shown in Figures 17 and 24, these studies revealed that cells pretreated with our BKV-targeted AONs showed significantly lower reinfection levels. In contrast, pretreatment of HK2 cells with SAN_73 and SAN_74 did not reduce reinfection levels to the extent observed with HYB_01, HYB_03 and HYB_11.
[0201] BKV-targeting AONs affect viral particle production The observed reduction in VP1 protein, a protein required for packaging BK virus DNA, should significantly affect the formation and release of new virus particles into the supernatant. Indeed, as shown in Figures 16, 23 and 33, most of our BKV-targeted AONs reduced virus particle production 7 days after infection, with HYB_01, HYB_03 and HYB_11 resulting in the greatest reduction. In contrast, SAN_73 and SAN_74 were found to only slightly reduce virus particle production. This mechanism may be involved in the reduction of (re)infection of local and distal cells in vitro, strongly suggesting that the uptake of our BKV-targeted AONs in renal proximal tubule epithelial cells after kidney transplantation could be an effective therapeutic modality for preventing BKV activation and / or transmission.
[0202] BKV-targeted AONs regulate TAg splicing. To gain mechanistic insight into how our BKV-targeted AONs lead to the reduction of TAg and VP1 mRNA as described herein, we performed RNA-seq of RNA collected from HK2 cells treated with scrambled AONs, HYB_01, HYB_03, HYB_11, HYB_14, SAN_73 or SAN_74, which were then infected with BKV for 2 hours. After washing, the cells were cultured for 7 days, after which RNA was collected and assessed for signs of degradation in a bioanalyzer. Equal amounts of RNA were then ribo-depleted and subjected to library preparation before RNA-seq. Consistent with our above-mentioned reduction of TAg and VP1 mRNA in HK2 cells, the coverage of BKV genomes from cells treated with scrambled control (Scrambled), HYB_14, or SAN_73 and SAN_74 was clearly higher than that treated with BKV-targeted AONs (Figure 42). To analyze the changes in BKV splicing, both human and BKV genomes were submitted for sequence alignment, and paired-end reads were aligned using Bowtie.
[0203] EventPointer was applied to quantify alternative splicing in the samples. Specific GTF files containing the different transcripts of the virus were used. This algorithm seeks to identify possible alternative splicing events, relating each transcript to its possible alternative pathways. To evaluate splicing in a highly complex pre-mRNA such as TAg, the pre-mRNA was decomposed into unique splicing events, and the TAg pre-mRNA was first separated into seven fragments. At each junction, the percentage of splicing in (PSI), defined by the frequency at which a splicing event was detected, was measured. This resulted in four unique alternative splicing events occurring at high frequency in all conditions as measured by EventPointer. The frequency of these events was scored using Kallisto software, resulting in a quantification per transcript (units per million transcripts). After statistical testing for significance, significant changes in splicing were observed at the exon 1-intron junction of TAg, precisely the site where our AONs were predicted to bind and affect splicing (Figure 35). Here, the upper panel provides a schematic diagram of the proper splicing events in TAg pre-mRNA, which are subsequently resolved into unique splicing events as shown in the lower panel. In the case of splicing event 1, HYB_01 results in a highly significant modulation of the splicing pattern for the truncated T antigen (P=0.0108), as the alternative splice acceptor site is preferentially used (Z-score=2.5484) compared to HK2 cells treated with scrambled control AON. Similarly, in the case of splicing event 2, highly significant changes in splicing are detected (p=0.0149), but HYB_01 results in the preferential production of small t antigen (tAg), unlike TAg (Z-score-2.4342). In contrast, no significant splicing changes are detected in cells treated with HYB_14, SAN_73 or SAN_74.The lack of splicing regulation for SAN_74 is particularly striking given that this AON also bridges the exon 1-intron junction, strongly suggesting that the size of our AON (20 nt as opposed to 16 nt long) plays a role in determining its ability to affect TAg splicing, potentially as a result of steric hindrance.
[0204] Furthermore, the data shown in Figure 35 also suggest that regulation of splicing at the exon 1-intron junction (splice event 2) also influences the splicing decision occurring within exon 2 (splice event 1). Thus, our BKV-targeted AON appears to trigger mutually exclusive or complex splicing events downstream of the TAg pre-mRNA. These studies are based on biological n=3.
[0205] Supporting evidence that our BKV-targeting AONs mediate splicing changes of TAg was obtained by performing long-range PCR using high-fidelity Phusion polymerase. As shown in Figure 43, compared to cells treated with scrambled control, dramatic changes in the use of truncated T antigen acceptor sites (splicing event 1 in Figure 35) were observed for HYB_01 and HYB_11, and more subtle changes were revealed for HYB_03. These data confirmed that AONs targeting exon 1-intron junction significantly affect splicing decisions within exon 2.
[0206] To gain further insight into the splicing-mediated effect of our AONs on BKV TAg, we used PacBio sequencing to generate long sequence reads of TAg, where primers binding to the 5' and 3' ends of TAg were used to amplify the full-length TAg pre-mRNA. These studies may provide precise insight into the precise use of individual splice sites within TAg, as well as potential mutually exclusive or complex events shown in our RNA-seq data. RNA degradation was assessed in a bioanalyzer, and PCR products were size-selected after target enrichment by PCR. cDNA libraries were prepared, ends were repaired, adapters were ligated, DNA was purified, and DNA was sequenced on a SMRTbell. Subreads were then converted into circular consensus reads (insertion sequence reads). As shown in Figure 36, consistent with our RNA-seq data, these studies suggest that AONs targeting TAg exon 1-intron acceptor affect the use or access to this splice site. Our BKV targeting AONs, especially HYB_01, reduce the level of TAg produced (left panel; left bar) and shift small t antigen and unspliced large T antigen to high levels (left panel; center and right bar, respectively). Moreover, the data provide further support for AON-mediated regulation of truncated T antigen splicing (right panel).
[0207] It is important to note that the efficacy of our BKV-targeting AON in regulating TAg splicing at exon 1-intron junctions shown herein may result in the use of (alternative) cryptic splice donor sites. The possible use of upstream cryptic splice sites (the coding sequence part of exon 1) or downstream cryptic splice sites (the intron part before exon 2) may result in frameshifted mRNA, which usually results in the introduction of premature stop codons. It has been demonstrated that these abnormal transcripts can be rapidly degraded in cells by nonsense-mediated decay mechanisms (Hug, N., et al., Nucleic Acids Research, 2016). Importantly, perhaps due to this rapid processing, the majority of these abnormal transcript forms go undetected.
[0208] Nevertheless, our quantitative and qualitative analysis of the remaining TAg transcripts clearly suggests that our BKV-targeted AON induces a significant reduction in TAg mRNA levels and at the same time affects the balance of mRNA formed as a result of pre-mRNA splicing. These data implicate the dual regulation of TAg expression and splicing as a powerful means to attenuate BKV particle production and infectivity.
[0209] In vivo uptake of BKV-targeted AONs Our data generated in vitro for BKV-targeted AONs chemically modified to include 2'-O methyl (2'-OMe) modification of the ribose sugar on each nucleotide in the antisense oligonucleotide. Importantly, we consistently found that the uptake of AONs in vivo was significantly improved when the 2' hydroxyl group was replaced with a 2'-methoxy (2'-MOE) group. Therefore, we modified our lead compound, HYB_01, to have an overall phosphorothioate backbone and 2'-MOE groups, and injected this AON intravenously through the tail vein into C57BL / 6J mice. 24 hours after injection, the mice were sacrificed, and the kidneys, liver, spleen, brain, and muscle were harvested and sectioned. As shown in the immunohistochemical staining in Figures 44 and 45, HYB_01 showed excellent uptake in the renal cortex, especially in the proximal tubular epithelial cells of the kidney (as evidenced by uptake in winged bean lectin (LTL)-positive cells in the kidney). In addition, HYB_01 was also detectable in Kupffer cells of the liver, but not in the brain (see Figure 45). Furthermore, their AONs were detectable in the white pulp of the spleen, but only minimally detectable in the heart, and not detectable in the muscle (data not shown).
[0210] (TAg splicing targeting AONs against other polyomaviruses) Although JC virus (JCV) has been demonstrated to infect proximal tubular epithelial cells of the human kidney, the inventors have repeatedly attempted to achieve this without success. Therefore, the inventors decided to infect other human cells known to be susceptible to JC virus and known to play a role in the development of JCV-associated pathophysiology, namely astrocytes. For these studies, the inventors pretreated human induced pluripotent stem cell-derived astrocytes or human primary astrocyte cell lines with one of our five JCV-targeting AONs (Figure 37), namely HYB_15-19 (at a concentration of 50 nM per AON for 4 hours), and subsequently infected those cells with JCV for 10 min. 4.5 TCID50 JCV cells were infected overnight at a titer of 1000 mg / mL (based on infection of Cos-7 cells 7 days after infection, information provided by the supplier). As shown in Figures 38 and 39, consistent with our observation that targeting the exon 1-intron junction of BKV TAg reduced the mRNA expression levels of TAg and VP1, HYB_15, HYB_16 and HYB_17 significantly reduced the mRNA expression levels of both JCV TAg and VP1 in iPS cell-derived astrocytes (n=1). Furthermore, in primary human astrocytes, we observed a significant reduction in the mRNA expression levels of JCV TAg and VP1 upon administration of various titers of JCV. (Figures 40 and 41; n=2).
[0211] [Table 7]
Claims
1. An antisense oligonucleotide of 12 to 30, preferably 17, 18, 19 or 20 to 30 nucleobases in length comprising a sequence which is the reverse complement of a contiguous stretch of at least 12 nucleobases of polyomavirus T antigen pre-mRNA, said antisense oligonucleotide being capable of modulating splicing of said T antigen pre-mRNA in a cell, said antisense oligonucleotide comprising at least 12 contiguous nucleobases of SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; SEQ ID NO:6; SEQ ID NO:7; SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10; SEQ ID NO:11; SEQ ID NO:12; SEQ ID NO:13; SEQ ID NO:14; SEQ ID NO:15; SEQ ID NO:16; SEQ ID NO:17; SEQ ID NO:18; SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:22; SEQ ID NO:23; SEQ ID NO:24; SEQ ID NO:25; SEQ ID NO:26 or SEQ ID NO:
27.
2. An antisense oligonucleotide comprising at least 12 consecutive nucleic acid bases of SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; SEQ ID NO:6; SEQ ID NO:7; SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10; SEQ ID NO:11; SEQ ID NO:12; SEQ ID NO:13; SEQ ID NO:14; SEQ ID NO:15; SEQ ID NO:16; SEQ ID NO:17; SEQ ID NO:18; SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:22; SEQ ID NO:23; SEQ ID NO:24; SEQ ID NO:25; SEQ ID NO:26 or SEQ ID NO:27, wherein the at least 12 nucleotides comprise the reverse complement of a splice donor sequence or a splice acceptor sequence of a respective polyomavirus large T antigen pre-mRNA.
3. 3. The antisense oligonucleotide of claim 1 or claim 2, which comprises a modification that renders the mRNA-oligonucleotide duplex resistant to the action of RNase H.
4. 4. The antisense oligonucleotide of any one of claims 1 to 3, comprising at least one nucleobase having a modified polymer backbone, preferably a 2'-O-methyl (2'-O-Me), 2'-O-methoxyethyl (2'-MOE), 2'-S-constrained-ethyl (2'-cEt), locked nucleic acid (LNA), peptide nucleic acid (PNA) or morpholino (PMO) nucleotide.
5. or comprising at least 17, preferably at least 18, 19, preferably at least 20 consecutive nucleobases of SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; SEQ ID NO:6; SEQ ID NO:7; SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10; SEQ ID NO:11; SEQ ID NO:12; SEQ ID NO:13; SEQ ID NO:14; SEQ ID NO:15; SEQ ID NO:16; SEQ ID NO:17; SEQ ID NO:18; SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:22; SEQ ID NO:23; SEQ ID NO:24; SEQ ID NO:25; SEQ ID NO:26 or SEQ ID NO:27, or The antisense oligonucleotide of any one of claims 1 to 4, comprising at least 17, preferably at least 18, 19, preferably at least 20 contiguous nucleobases of SEQ ID NO:7; SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10; SEQ ID NO:11; SEQ ID NO:12; SEQ ID NO:13; SEQ ID NO:14; SEQ ID NO:15; SEQ ID NO:16; SEQ ID NO:17; SEQ ID NO:18; SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:22; SEQ ID NO:23; SEQ ID NO:24; SEQ ID NO:25; SEQ ID NO:26 or SEQ ID NO:27, with one mismatch, which mismatch is not the first or last nucleotide of the contiguous stretch.
6. 13. A method for inhibiting replication of a polyomavirus in a cell, the method comprising providing to a cell infected with the polyomavirus an antisense oligonucleotide according to any one of claims 1 to 5 or 12.
7. A method of preparing a graft for transplantation, the method comprising providing donor cells, preferably donor kidney cells, with an antisense oligonucleotide according to any one of claims 1 to 5 or 12.
8. A method of treating a polyomavirus infection in a subject, the method comprising administering to an individual in need thereof an antisense oligonucleotide according to any one of claims 1 to 5.
9. The method of claim 8 , wherein the individual is an immunocompromised individual.
10. 10. The method of claim 8 or claim 9, wherein the individual is a kidney or renal cell transplant recipient.
11. 13. A method of administering to an individual an antisense oligonucleotide for hybridization to a complementary RNA sequence in renal cells of said individual, said method being characterized in that said antisense oligonucleotide is an oligonucleotide according to any one of claims 1 to 5 or 12.
12. An antisense oligonucleotide comprising a modification which renders the duplex between the antisense oligonucleotide and the target mRNA resistant to the action of RNase H, the antisense oligonucleotide comprising the sequence of SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; SEQ ID NO:6; SEQ ID NO:7; SEQ ID NO:8; SEQ ID NO:9; SEQ ID NO:10; SEQ ID NO:11; SEQ ID NO:12; SEQ ID NO:13; SEQ ID NO:14; SEQ ID NO:15; SEQ ID NO:16; SEQ ID NO:17; SEQ ID NO:18; SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:22; SEQ ID NO:23; SEQ ID NO:24; SEQ ID NO:25; SEQ ID NO:26 or SEQ ID NO:27, with no mismatches or with one or two mismatches.
13. 1. A method for inhibiting the replication of polyomavirus in a cell, the method comprising providing to the cell an antisense oligonucleotide of 12 to 30 nucleotides in length comprising a sequence which is the reverse complement of a contiguous stretch of at least 12 nucleobases of polyomavirus large T antigen pre-mRNA, the antisense oligonucleotide being capable of modulating splicing of the large T antigen pre-mRNA.
14. The method according to claim 13, wherein the antisense oligonucleotide is an antisense oligonucleotide according to any one of claims 1 to 5 or 12.
Citation Information
Patent Citations
Compositions and methods for inhibiting expression of jc virus genes
JP2009535039A
Inhibition of polyomavirus replication
JP7532257B2
Anti polyomavirus compounds
WO2012143427A1
Gene editing methods and compositions for eliminating risk of JC virus activation and PML (progressive multifocal leukoencephalopathy) during immunosuppresive therapy
WO2017100431A2
